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RESUMO 
A leishmaniose é uma doença negligenciada típica das áreas tropicais e subtropicais. 
Contudo, está a tornar-se comum nos países desenvolvidos, devido ao aumento da 
população imunossuprimida e à crescente frequência de viajantes pelo mundo. 
São conhecidas mais de 20 espécies de Leishmania que infectam e causam doenças 
em humanos. Diferentes espécies podem causar distintas formas de doença, que podem 
variar desde manifestações cutâneas benignas até à morte. 
Hoje em dia, a quimioterapia é quase a mesma de há 50 anos atrás, com poucas 
excepções como a introdução miltefosina e a anfotericina B (AmpB). Os antimoniais são 
fármacos de primeira linha. São altamente tóxicos e a sua resistência é já um problema. 
De todos os fármacos usados hoje em dia, só a miltefosina é de administração oral. A 
maior parte dos antileishmaniais disponíveis têm pelo menos uma das seguintes 
limitações: toxicidade, alto-custo, ineficácia, resistência ou necessidade de 
hospitalização. 
Até agora, o desenvolvimento de fármacos contra a leishmaniose foi baseado em 
extensão de indicações terapêuticas de moléculas já existentes ou novas formulações de 
antileishmaniais já usados. Por isso, é urgente desenvolver novas moléculas que 
superem os problemas existentes. Têm sido usadas muitas estratégias para identificar 
movas moléculas. Um método promissor é o high throughput screening (HTS) de 
pequenas moléculas. 
O HTS necessita de um modelo biológico robusto e bem estabelecido, capaz de 
responder a todas as solicitações e questões. Para tal, o objectivo deste projecto é 
desenvolver um modelo de infecção ideal para a descoberta de novos fármacos. 
Foram optimizados modelos de infecção para L. amazonensis, L. braziliensis, L. 
donovani e L. major em linhas celulares de macrófagos humanos (THP-1) e de ratinho 
(Raw 264.7). Estes modelos foram optimizados, tendo em conta os diferentes tropismos 
e dinâmicas de infecção das diferentes espécies. As 4 espécies estudadas são 
responsáveis por formas de doença completamente diferentes, desde cutânea a visceral. 
Portanto, este projecto fornece informação muito útil que pode melhorar o HTS de 
novos fármacos eficazes contra Leishmania. Estas condições ideais de infecção irão 
proporcionar uma selecção de compostos activos adequados a cada espécie que causa 
diferentes formas de doença. 
 
PALAVRAS-CHAVE: Leishmania, leishmaniose, antileishmaniais, high throughput 
screening 
 vii 
ABSTRACT 
Leishmaniasis is a neglected disease typically indigenous to tropical and subtropical 
areas. However, it is becoming more common in developed countries, because of the 
increasing immunosuppressed population and the higher frequency of travelers around 
the world. 
More than 20 Leishmania species are known for infecting and causing disease in 
humans. Different species can cause distinct leishmanial disease forms, which can range 
from benign cutaneous manifestations to death. 
Today, chemotherapy is almost the same as 50 years ago, with few exceptions such 
as miltefosine and amphotericin B (AmpB). Antimonials are first line drugs, but are highly 
toxic and resistance is already an issue. From all the drugs currently used, only 
miltefosine has oral administration. Most of the antileishmanials available are not adapted 
to the field, and have at least one of the following limitations: toxicity, high cost, non-
effectiveness, resistance or hospitalization requirement. 
Until now, drug development for leishmaniasis was based on label extension of 
already existing molecules or new formulations of old antileishmanials. Therefore, there is 
an urgent need to develop new antileishmanial molecules, in order to bypass or overcome 
the existing problems. To identify these molecules, many strategies have been used. One 
promising method to find new active chemicals is the high throughput screening (HTS) of 
small molecules, in order to select antileishmanial scaffolds. 
HTS must have a strong and well established biological model able to answer all 
requests and questions. For that purpose, this project’s aim is to develop an optimal 
infection model for antileishmanials’ drug screening. 
Infection models for L. amazonensis, L. braziliensis, L. donovani and L. major were 
optimized, and THP-1 (human) and Raw 264.7 (murine) macrophage cell lines were used 
as host cells. These infection models account for each specie’s tropism and infection 
dynamics. These 4 species studied are responsible for completely different forms of 
disease, cutaneous and visceral. 
Therefore, this project provides very useful information that can improve HTS for new 
antileishmanial drugs. With this valuable new data, optimal infection assays can be 
carried and optimal HTS results will be achieved. These optimal conditions will provide 
active compounds selection and testing against causative species of each disease form. 
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 I – Introduction 
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Leishmaniasis is a neglected disease that is becoming increasingly relevant in 
developed countries. Due to the great number of human infective Leishmania species, 
many disease forms can occur. Different species have different tropism, infection 
dynamics, immunology, and sensitivity to drug therapy. Current therapy often fails and 
has many limitations. Therefore, it is needed to develop new antileishmanial drugs. In 
order to do so, drug discovery processes must be adapted so that it incorporates earlier 
stages of the disease with different species. This way, future therapy will be more 
effective and drug resistance development can be avoided. 
An effective method for such drug discovery is HTS. HTS relies on a biological model 
of an infection that is able to mimic the in vivo situation. This way, the screened molecules 
will be subjected to the closest to the real infection situation. We must consider that 
different species have different tropisms, infection strategies, and replication dynamics. 
For that, every infection model must be adapted to test these differences. At the time of 
writing of this thesis, as far as the authors are aware, there were no studies with this 
purpose. 
In this thesis we want to contribute to Leishmania drug screening, providing optimized 
infection protocols for 4 Leishmania species: L. amazonensis, L. braziliensis, L. donovani, 
and L. major, for human (THP-1) and murine (Raw 264.7) macrophage cell lines. 
Chapter II starts with a brief exposure about neglected tropical diseases (NTDs) and 
their impact on our world. After, there is a description about Leishmania parasite biology 
and the disease forms it may cause. It is also described Leishmania’s complex survival 
and infection strategies. On the last point, there is a summary about Leishmania induced 
immunological responses. 
In Chapter III, current therapy used to treat all forms of leishmaniasis is extensively 
described. Also future therapy is discussed, focusing in new drugs that are currently being 
evaluated in clinical trials. 
In Chapter IV, drug discovery process is exposed, and strategies to develop new 
drugs are described. Also, cell-based assays for HTS are explained, with special attention 
to Leishmania infection models. In the end, cellular imaging and confocal microscopy are 
high lightened. 
In Chapter V, materials and methods are extensively described: cells culturing, 
infection and replication assays, and image analysis. 
In Chapter VI, infection is phenotypically analyzed. Both infection images and 
statistical analysis are shown and properly discussed. Also, image-mining process is 
revealed. Finally, in Chapter VII all results are summarized. 
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 II – Leishmania 
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1. Neglected Tropical Diseases (NTDs) 
According to the World Health Organization (WHO), NTDs are chronic infectious 
diseases commonly associated with poor, warm and humid scenarios. Most are parasitic 
diseases, spread by insect vectors, contaminated water or soil. NTDs keep being 
perpetuated by poor standards of living and hygiene. They are pathologically different, but 
all of them can cause severe disability and life-long impairment. Many people are infected 
with 2 or more diseases at the same time (1). 
NTDs are common among poor populations in developing countries, mainly in Africa 
and South America. These diseases put more than 1 billion poor people in poverty, and 
are an important economic burden in endemic countries. They also lead to social 
stigmatization and discrimination (1, 2). 
According to WHO 2010 fact list, the top most prevalent NTDs are (1): 
1. Soil-transmitted helminthiasis, more than 1 billion people infected; 
2. Schistosomiasis, more than 200 million people infected, 120 million are 
asymptomatic and around 20 million are severely symptomatic; 
3. Lymphatic filariasis, around 120 million people infected. It is the second leading 
cause of disability worldwide; 
4. Blinding trachoma, around 80 million people infected and 6 million are blind. It is 
the first infectious cause of blindness; 
5. Onchocerciasis, around 37 million people infected, mainly in Africa. Causes severe 
skin disease, visual impairment, blindness, and shortens life expectancy by 15 
years; 
6. Chagas disease, 13 million people infected. Mostly in Latin America, but with new 
endemic trends due to migration, blood transfusion, congenital via and organ 
donation; 
7. Leishmaniasis, more than 12 million people infected, 350 million are at risk, and 
there is 1.5 to 2 million new infections per year. 
NTDs do not cause massive deathly outbreaks, and tend not to affect richer countries. 
Therefore, they do not get media attention, are not included in health agendas and 
budgets setting (1). However, these diseases are becoming more common in the 
developed world, due to the increasingly larger immunocompromised population (3). In 
the end, there is no funding either for diagnostics and treatment, or research and 
development (R&D). NTDs’ market is poor, and there are no real economic benefits in it 
(1). Only 1% of newly developed drugs are for NTDs (4). 
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NTDs disease burden assessment is difficult to measure. Disease burden is defined 
as the prevalence or incidence of disease morbidity and mortality. Currently, the disability 
adjusted life year (DALY) system is the most used method for disease burden 
measurement. Global Burden of Diseases (GBD) assessments, provided by WHO and 
World Bank, developed this system. The GBD program aims at cost-effective 
implementation of health programs (2, 5, 6). 
DALY’s goal is to quantify and compare regional aggregate and worldwide health 
burden. DALY is to measure disease impact for all health states, with an average disease 
impact per person, in a non-subjective manner. This system has been used to measure 
disease impact by health policy-makers and funding institutions, in order to prioritize 
investments. However, it might underestimate NTDs real priorities. According to World 
Bank and GBD, a serious investment in NTDs treatment can increase in 4 years life 
expectancy for the world’s poorest 20% population (2). 
Leishmaniasis DALY estimates is based on regional incidence and prevalence, case-
fatality rates, and disability weights (5). Current leishmaniasis disease burden 
measurement do not account clinical and epidemiological diversity, medical, social and 
economic impact (6). 
Current leishmaniasis statistics have not been updated since 1991. It is only notifiable 
in 33 of 88 endemic countries. Also, in many countries, most cases are treated by non-
governmental organizations or by private sector, and they tend do not report the cases. 
One Sudanese study estimates that 91% of all deaths due to visceral leishmaniasis (VL) 
were undiagnosed. Data from a village-based study in India suggest that 20% of VL 
patients, poor and female, died before definitive diagnosis (5). 
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2. Leishmaniasis 
Leishmaniasis is a vector-borne disease, and it can be caused by more than 20 
Leishmania species (Table 1). It can cause varied clinical syndromes, from localized skin 
ulcers to lethal systemic disease. Among tropical diseases, it is the second in mortality, 
the fourth in morbidity, and, in terms of DALYs, the third most important vector-borne 
disease. Nevertheless, leishmaniasis is one of the most neglected diseases, because 
resources invested in diagnosis, treatment, and control are very rare. It is extremely 
associated with poverty conditions, and usually requires prolonged and expensive drug 
therapy. Other factors such as malnutrition or human immunodeficiency virus (HIV) con-
infection can alter clinical course, complicating therapeutic strategies and outcome (5, 6). 
Table 1. Leishmania species and disease forms. 
Disease New World species Old World species 
Cutaneous L. (L.) mexicana L. (L.) major 
  
L. (L.) mexicana 
complex L. (L.) amazonensis 
L. (L.) major 
complex L. (L.) tropica 
   L. (L.) pifanoi  L. (L.) aethiopica 
   L. (L.) venezuelensis   
  L. (V.) subgenus L. (V.) braziliensis   
   L. (V.) peruviana   
   L. (V.) lansoni   
   L. (V.) naiff   
   L. (V.) panamensis   
   L. (V.) guyanensis   
L. (L.) amazonensis L. (L.) aethiopica Diffuse 
Cutaneous 
L. (L.) mexicana 
complex L. (L.) pifanoi 
L. (L.) major 
complex  
Mucocutaneous L. (V.) subgenus L. (V.) braziliensis     
Visceral L. (L.) chagasi* L. (L.) donovani 
  
L. (L.) donovani 
complex   
L. (L.) donovani 
complex L. (L.) infantum* 
* CL cases caused by L. (L.) chagasi and L. (L.) infantum have been reported (9-11). 
Leishmaniasis incidence is geographically heterogeneous (5). This disease is 
transmitted in urban, peri-urban, and rural areas (5), present in cities, deserts and rain 
forests on every continent, except Australia and Antarctica. More than 90% of reported VL 
cases are in Bangladesh, Brazil, Ethiopia, India, Nepal, and Sudan, and 90% of 
cutaneous leishmaniasis (CL) cases are reported in Afghanistan, Algeria, Brazil, Pakistan, 
Peru, Saudi Arabia, and Syria (5-7). 
However, population migration, international traveling, lack of vaccines, vector control, 
international conflicts and resistance development have been increasing the number of 
infections throughout the world (8). Non-vectorial and human vertical transmission have 
been reported, but are rare (9). Other forms of human transmission have been reported, 
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such as iatrogenic route, especially in co-infection Leishmania-HIV cases and blood 
transfusion. Drug addicts are an important health problem issue, sharing contaminated 
needles (9, 10). 
The factors determining the kind of clinical manifestation depend upon host genetics, 
general health and immune status, which can promote protective or susceptibility factors, 
host environment, previous immunological experience, infecting species, geographic 
localization and the vector species (11). 
Leishmaniasis mortality is usually related to VL. Nevertheless, CL deaths occur, even 
though they are rare, usually due to co-infections or treatment complications. Death age 
varies according to the endemic setting. Younger groups are affected in established VL 
transmission conditions and older age groups are affected in new VL endemic areas. 
Because of the relatively benign nature of CL, inaccessibility of health services in rural, 
endemic areas, and the common non-availability of treatment, there is severe under-
reporting. Also, VL has similar clinical symptoms to other diseases, which are more 
prevalent in endemic areas, such as malaria and schistosomiasis, which aggravates the 
under-reporting issue. Co-infection with other diseases may occur, such as malaria or, 
more recently, HIV. CL and VL have become an opportunistic infection of HIV/acquired 
immune deficiency syndrome (AIDS) patients. VL increases mortality risk by more than 3 
folds (6). 
VL, also known as kala-azar, is usually caused by L. donovani and L. infantum. VL is 
a chronic systemic disease characterized by fever, hepatosplenomegaly, 
lymphadenopathy, pancytopenia, weight loss, hypergammaglobulinemia, weakness, and, 
eventually, leads to death. Life threatening complications include immunosuppression, 
secondary bacterial infections, hemorrhage, anemia, and, during pregnancy, fetal 
wastage or congenital leishmaniasis (5, 6). During VL infection, there is a heavy parasite 
burden in spleen, liver, and bone marrow (12). VL disease can last up to 2.5 months, 
depending on infecting species, genetic host factors, and immunosuppression, 
malnutrition or HIV/AIDS co-infection. If not treated, VL patients do not tend to cure 
spontaneously, with 95% fatality rate. Depending on the drug and route of administration, 
the treatment itself can cause disability, due to severe toxicity, which can cause myalgia, 
gastroenteritis, pancreatitis, diabetes, hepato or cardiotoxicity (6). Even in treated 
patients, fatality rates can be 10% or higher. Jaundice, wasting, severe anemia, and HIV 
co-infection are commonly associated with increased risk of mortality (5). 
A higher female incidence of VL has been reported. On average, women are ill longer 
than men, and are more likely to die from the disease. This might be explained by the 
social barriers women are confronted with when they seek healthcare, or because of their 
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poorer nutritional status, which may aggravate morbidity and mortality. Children have the 
highest risk for VL development, and fatality rate can approach 10% (5). 
Post kala-azar dermal leishmaniasis (PKDL) is a chronic rash, seen in apparently 
cured VL patients, mainly in South Asia and the Horn of Africa. PKDL presents 
erythematous or hypopigmented macules that may progress to plaques or nodules. In 
Sudan, up to 60% VL patients develop PKDL; in South Asia, it is estimated to be from 10 
to 20%. It is known that some years after VL incidence peaks, PKDL cases show up. 
PKDL patients remain infectious for years to decades, and require prolonged 
antileishmanial treatment. Some of them die during treatment, due to antimonial severe 
cardiotoxicity (5). 
CL, also known as oriental sore, is the most common form of leishmaniasis, and L. 
major, L. tropica, L. braziliensis, and L. mexicana mostly cause it. It is generally non-fatal, 
is limited to the skin and may cure spontaneously. Though, spontaneous cure is slow and 
depends on the infective species (5, 6). However, CL can evolve into a more severe 
disease, such as leishmaniasis recidivans or mucocutaneous leishmaniasis (MCL) (6). 
MCL, also known as espundia, is mostly caused by New World species (12). It usually 
occurs months or years after healing primary CL infection, commonly due to L. 
braziliensis. MCL can lead to nasal septum, palate, throat, and associated tissues total or 
partial destruction, which originates facial mutilation and, rarely, death due to airway 
malfunction. Leishmaniasis recidivans, localizes slowly and progressive in non-healing 
lesions. Diffuse CL (DCL) is a diffuse nodular non-ulcerating form of disease that does not 
heal spontaneously and is difficult to treat (5). CL promotes a protective immune 
response that circumscribes the parasite to inoculation site. On the other hand, DCL has 
a poor immune response, which leads to uncontrolled parasite spread on the skin (13). 
CL duration of disease is variable, and depends on the many infecting species. 
Clinical disease can spontaneously cure in 2 to 6 months, for L. major, but it can become 
chronic if not treated and become more severe, for L. tropica or L. braziliensis. For most 
species, if not treated, the disease lasts longer than 6 months. CL scars can be a social 
stigma, with great social impact, and may become a life-long burden. CL nodular lesions 
are similar to lepromatous leprosy, which deepens the stigma. Scars development 
depends on Leishmania spp., and type of clinical disease (5, 6). 
CL is a major financial burden on the infected person, direct family and public health 
system (5). A recent Indian study showed that each VL episode could cost 71% of an 
annual household income, with medical expenses and loss of income, due to physical, 
psychological or social burden. VL’s disability significance is comparable to disabling 
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leprosy, malaria episodes, dengue hemorrhagic fever, onchocerciasis and trachoma 
resulting in low vision. On the other hand, CL is in the range of malaria-induced anemia, 
hookworm-induced anemia, onchocerciasis-induced itching, and lymphatic filariasis 
characterized by hydroceles (6). 
Disease burden estimation should include duration of active disease and scars, 
economic burden, physical and emotional disability. In order to bypass under-reporting 
issues, there should be a recommendation to uniform leishmaniasis definition, including 
clinical and non-clinical leishmaniasis diagnosis standardized algorithms (6). 
As told before, leishmaniasis has been a disease typically endemic in poorer 
countries. However, these days, its epidemiology has evolved and it has become more 
present in more developed countries. Immunodepressed population and domestic dogs 
are the main reservoirs in these new endemic areas, and perpetuate Leishmania 
parasites’ life cycle. 
HIV infected individuals and people on immunodepressant therapy can develop 
leishmanial infection. Actually, HIV/AIDS patients are the most representative population 
of Leishmania infection in developed countries. In endemic areas, “HIV infection 
increases the risk of VL by a factor 100–1000” (14, 15). 
East African countries have an increasing number of Leishmania-HIV co-infection 
cases, reaching up to 34% (14). In Brazil the number of co-infection reported cases is 
lower than expected, because of free distribution of antiretrovirals and possible under-
reporting (5). Outside non-endemic areas, VL is an opportunistic infection in HIV patients 
(7), such as in Mediterranean countries. Portugal, Spain, France and Italy have more than 
1,500 cases of co-infection reported (16). Up to 70% of leishmaniasis adult cases are 
related to HIV infection, and 90% are from the countries listed before (17). 
Leishmania-HIV co-infected individuals are highly infectious to sandflies and can 
spread resistant parasites, which are an issue to control programs success (5). 
Immunocompromised patients can reactivate latent infections or be infected by zoonotic 
or anthroponotic transmission (9). The main reservoir of anthroponotic VL is the man, it is 
mainly caused by L. donovani and mostly occurs in Sudan, Ethiopia, India, Nepal and 
Bangladesh (16). 
High activity antiretroviral therapy (HAART) reduces prevalence of co-infection and 
improves survival rate. The increase of CD4+ T cell improves the control of leishmanial 
infection (18). VL promotes AIDS-defining illness conditions and its clinical progression, 
diminishing life expectancy. HIV-1 infection increases the risk of developing VL in 
endemic areas, enhances relapse occurrence and diminishes drug response. Without 
HAART, most co-infected patients die within 2 years, and relapse rate after treatment can 
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be up to 100% (5, 14, 15). HIV patients without severe immunosuppression, have 
manifestations similar to immunocompetent persons (5). 
Leishmania infection maintenance in these new foci also relies on dogs’ infection. 
Canine leishmaniasis (CanL) is more prevalent and widely distributed than VL, and it 
does not correlate with human disease prevalence. CanL is caused by L. infantum, and is 
endemic in China, Pakistan, Latin America (16), and Mediterranean countries. In southern 
Europe, it is considered a rural disease, but its prevalence in urban areas is increasing. In 
Mediterranean area, dog’s seroprevalence ranges from 10 to 37%. More than half of 
seropositive dogs are asymptomatic, and they are an important reservoir for sandflies. 
Stray dogs usually spread and increase infection (9, 19). 
Genetic predisposition, immunodepression, malnutrition, parasite load, species 
virulence, and phlebotomine saliva are important risk factors (16). CanL clinical 
manifestations are pleomorphic: nonpruritic skin lesions, such as exfoliative dermatitis 
and ulcerations, local or generalized lymphadenopathy, weight loss, poor appetite, ocular 
lesions, epistaxis, lameness, onycogryphosis, renal failure, diarrhea, musculoskeletal 
system abnormalities and eye lesions (10, 19). Standard treatment for dogs is meglumine 
antimonate for 28 days and allopurinol (16). Among dogs, the high prevalence of infection 
has suggested other forms of transmission, such as blood transfusion, venereal routes, 
and transplacental transmission (10). 
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3. Leishmania Biology 
3.1 Leishmania 
Leishmania is a protozoan parasite from the order Kinetoplastida, family 
Trypanosomatidae, and the causative agent of leishmaniasis. There are 30 species 
known to infect mammals, and 21 of them cause human infection (7, 20). Primitive 
Leishmania was divided into Sauroleishmania and Leishmania. Sauroleishmania species, 
L. (S.) tarentolae and L. (S.) gymnodactyli, infect reptiles, and current Leishmania species 
infect mammals. Sauroleishmania only infects lizards, so it is non-pathogenic for humans 
(21, 22). The genus Leishmania has 2 subgenera, Leishmania (Leishmania) and 
Leishmania (Viannia) (21). 
Leishmania parasites are dimorphic, alternating between promastigote and 
amastigote forms during their life cycle (Figure 1). In the mammalian host, these protozoa 
are macrophage-dendritic cell (DC) lineages obligate intracellular parasites, and are 
called amastigotes. The promastigotes are the infective form and can be found in the 
insect vector, the sandfly (20). Promastigotes are phagocytized by macrophages, DCs, or 
neutrophils, where they transform into amastigotes. Amastigotes multiply by simple 
division and proceed to infect other mononuclear phagocytic cells. Sandflies ingest 
infected cells, and amastigotes differentiate back into promastigotes (7, 23). 
 
Figure 1. Leishmania’s life cycle (24). 
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3.2 Species differences 
The phylogenetic distance between L. mexicana/L. amazonensis and L. major (CL 
strains) is identical to the distance between L. mexicana/L. amazonensis or L. major and 
L. donovani (VL strains). Also, mammalian reservoir hosts are different and show some 
specificity for each Leishmania species, suggesting an evolutive adaptation. So, virulence 
factors and immunogenetics of host susceptibility and resistance vary greatly among 
species. Some genes are known to be commonly involved in L. major, L. donovani, and L. 
mexicana infection, such as H-2 and H-11, but others, such as NRAMP/Lsh, only 
influence infection development for L. mexicana. There are specific genes related to 
disease visceralization. Infection control is very complex, and a multigenic combination 
may lead to healing or non-healing (25). 
Different Leishmania species can cause a wide range of clinically distinct diseases. 
The evolution of visceralizing or disseminating phenotype of some species, such as L. 
donovani or L. braziliensis, and localized phenotype of others, such as L. major, is still 
unclear. The interaction host-parasite and immune response suggest an antigen-
dependent pattern of disease, which depends on the species. VL disease clearly depends 
on immune response, receptors, co-receptor and parasite tropism (21). Nevertheless, 
there is a high gene conservation for L. major, L. infantum and L. braziliensis (26). 
Berman et al. (1981) study showed that CL strains temperature optima for amastigote 
replication is 35 °C and for VL strains is 37 °C. Pereira et al. (1958) had already shown 
the relationship between skin and environmental temperature. In vivo CL strains multiply 
more rapidly at lower temperatures than VL strains. Cutaneous and mucocutaneous 
localization of CL might be related to this fact, so as primarily visceral and bone marrow 
localization for VL strains (27). 
Parasitophorous vacuoles (PVs) are different between species. L. mexicana complex 
parasites, L. mexicana, L. amazonensis, and L. pifanoi, reside in communal PV, which get 
bigger during infection. On the other hand, L. donovani complex parasites, L. donovani, L. 
chagasi, and L. infantum, reside in tight individual PVs from where daughter cells 
segregate into their own PVs (28). Leishmania parasites reside inside PVs so they can 
evade the immune system, resisting to hydrolases and peptidases digestion (13). 
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3.3 Metacyclogenesis 
Different Leishmania life cycle forms (Figure 2) are distinguished by their nutrients 
requirement, growth rate, division ability, expression of surface proteins, and morphology 
(29). During metacyclogenesis, there is a differential and enhanced expression of 
virulence factors (25). VL strains have faster metacyclogenesis than CL strains, which 
promote better ability to infect, and leads to stronger pathogenic effects (30). 
Metacyclogenesis can be triggered by low pH, high temperatures, such as human body 
temperature, and elevated CO2 concentration (29, 31). 
 
Figure 2. Leishmania’s metacyclogenesis morphological evolution (29). 
Procyclic promastigotes (Figure 3) have rapid division ability (32), are non-infective, 
have an elongated spindle shape and are 20 µm long (29), are weakly motile (31), and do 
not present apoptotic features. In vivo, they are in the insect’s midgut, and in vitro, they 
can be cultivated axenically (33). 
Metacyclic promastigotes (Figure 3), are not able to multiply, have higher infectivity 
ability, have a rounder shape, have a longer flagellum, show a swollen kinetoplast, lack 
nuclear structures, and present apoptotic features. Metacyclic promastigotes have 
surface molecules that are complement-resistant, being more resistant to lysis (29, 30, 
32, 33). They are at the insect’s thoracic midgut and proboscis, and are more common 
during stationary growth (34). Metacyclic promastigotes do not adhere to phlebotomine 
sandfly digestive tract. During metacyclogenesis, surface carbohydrates change at D-
galactose sites (30). 
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Figure 3. (A) Leishmania promastigote and (B) amastigote forms. The flagellar pocket marks the anterior cell 
end (29). 
Lipophosphoglycan (LPG) is a complex glycophospphatidylinositol-anchored 
phosphoglycan molecule on promastigote’s surface (25). LPG is over expressed in 
metacyclic promastigotes, and it is a complement resistance factor (35). Due to surface 
LPG differences during metacyclogenesis, peanut agglutinin (PNA), Arachis hypogea, is 
able to agglutinate procyclic promastigotes (PNA+). This method is used to separate 
procyclic promastigotes from metacyclic ones (PNA-) (30, 34). 
After inoculation in mammalian host cells, metacyclic promastigotes differentiate into 
amastigotes, residing inside a vacuole with lysosomal features, the PV. Amastigotes are 
intracellular organisms, non-motile, with reduced size (around 4 µm), with a much-
reduced flagellum located inside the flagellar pocket. They are acidophiles, and have an 
adapted energy metabolism (29). Amastigotes perpetuate infection, when they are taken 
during the insect vector’s blood meal (31). 
Intracellular macrophage environment promotes transformation into amastigotes (36). 
PVs import nutrients through the parasite surface and macrophage membranes. In order 
to survive to PV’s hostile environment, for example, L. amazonensis changes its basic 
electrical properties. K+ currents modifications explain sustained hyperpolarization elicited 
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by infection. Hyperpolarization appears to be related with macrophages activation and 
phagocytosis (37). 
Lysosomes change shape and content. In procyclic promastigotes, lysosomes are a 
large single vesicle at the anterior end of the cell. Amastigotes show megasomes, which 
represent 15% of total cell volume. These megasomes can be related to nutritional 
requirements and species virulence. The number of autophagosomes increases, and 
autophagy can be enhanced, which is a survival strategy (29). 
During metacyclogenesis, genetic expression changes, and there is a protein turnover 
(29, 31). However, because this process occurs in an environment poor in nutrients, de 
novo protein synthesis is limited (32). Studies made with L. braziliensis show differential 
mRNA transcripts expression throughout metacyclogenesis (38). A2 gene, an amastigote 
stage protein, which contributes to tissue tropism, is important for L. donovani virulence, 
and promotes visceralization (25). Peptidases content also change, and metacyclic 
promastigotes show higher proteolytic activity. Peptidases release the heme group, 
important for Fe metabolism. Hemoglobin is internalized as a lysosomal compartment. Fe 
may be also obtained from transferrin or lactoferrin (29). 
Post-translational protein modifications can be detected by mass spectrometry (MS) 
techniques. Many proteins exist throughout all Leishmania life cycle, but with different 
molecular weights and isoelectric points. Other proteins only exist in one of the life cycle 
stages. For instance, metacyclic promastigotes are more related to motility proteins. 
Overall, during metacyclogenesis, there is a down regulation of synthetic proteins and an 
up regulation of motility proteins. Also, there are specific modifications of mitochondrial 
enzymes (32). 
 
3.4 Virulence and infection strategies 
Since the first time of infection, strategies to enhance it and provoke a more virulent 
response are done, both by the parasite and by the insect vector. The sandfly saliva has 
exacerbating factors, such as anti-aggregation factors, vasodilators, anticoagulants and 
anti-haemostatics (31, 39). Luzomia longipalpis saliva and Leishmania parasites enhance 
macrophages recruitment and neutrophils in BALB/c mice (susceptible strain), but not in 
C57BL/6 (resistant strain) (39). 
In the mammal host, myeloid cells, such as macrophages, DCs and neutrophils, are 
Leishmania hosts, final or intermediate (39). After ingestion, parasites are sequestered 
from the host cell cytosol by a membrane that turns into PV (28). If procyclic 
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promastigotes are phagocytized together with metacyclic promastigotes, they will survive 
inside the neutrophils (33). Survival and virulence strategies are summarized on Table 2. 
Table 2. Long-term persistence mechanisms of intracellular pathogens in vivo (40). 
Pathogen entry into safe target cells     
 Fibroblasts    
  Neurons       
Pathogen resistance to host cell effector mechanisms  
 AO synthesis    
  Proteasomal activity   
  Metabolic salvage pathways     
Supression or avoidance of host cell effector mechanisms  
  Expression of NADPH oxidase or iNOS  
 Blockade of NADPH or iNOS phagosomal recruitment  
 Inhibition of phagosome-lysosome function  
  Exit into cytosol       
Pathogen-mediated immune deviation   
 Antigen presentation inhibition   
  Co-stimulatory cell surface molecules  
  IL-10    
 
  
 Regulatory/Supressive T cells (CD4+CD25+FoxP3+ Treg cells, CD4+CD25-
FoxP3-IL-10+ Th1 cells, CD4+FoxP3-IL-10+INF-γ- T cells) 
Phagocyte functions are suppressed by phosphatidylserine (PS) exposure on 
apoptotic cells membrane. PS is an apoptotic feature, which appears when the plasma 
membrane phospholipids symmetry is altered (33), and its recognition leads to 
Leishmania intracellular survival. If there are no apoptotic parasites, Leishmania will not 
induce in vivo disease. A purified apoptotic population will not cause disease, because 
these parasites are dying or already dead. A purified non-apoptotic parasite culture will 
also not be able to induce disease. When non-apoptotic and apoptotic parasites are 
injected into BALB/c mice footpad, these develop large lesions (33, 41). L. major parasite 
apoptotic death activates cysteine proteinases, permeabilizes mitochondrion, and 
destroys DNA (34). 
Amastigotes and metacyclic promastigotes can also have a silent phagocytic uptake, 
due to calreticulin exposure, which is also an apoptotic signal (42). Metacyclic 
promastigotes can be phagocytized by resident dermal mononuclear phagocytic 
leukocytes and/or by phagocytic leukocytes recruited from epidermis or blood. After an 
autophagic process, they differentiate into amastigotes. Mature mononuclear phagocytic 
leukocytes present colony-stimulating factor-1 receptor (CSF-1R), which regulates 
production, maintenance and function of phagocyte lineage derived macrophages (42). 
PS exposure in promastigotes occurs by apoptotic death or apoptotic mimicry. The 
first is for infection and the second for disease progression. This leads to a permissive 
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host suitable for survival and proliferation, which is an adaptative survival strategy of 
Trypanosomatids (41). Apoptotic features will reduce inflammation signals and help the 
parasite to evade the immune system, facilitating its “silent entry” into neutrophils. 
Nutrient shortage in stationary phase and sandfly gut can be an explanation for apoptosis 
start with PS exposure (33, 34). 
PS+ amastigotes induce transforming growth factor (TGF) β and interleukin (IL) 10 
production. They silence polymorphonuclear (PMN) cells effector functions, allowing 
intracellular survival of non-apoptotic parasites. Apoptotic Leishmania parasites ratio 
increases during in vitro culture. In stationary phase, more than 50% of the parasite’s 
population can be apoptotic (34). 
PMN cells are the first line of organism defense against infectious agents or 
exogenous substances. These cells have a lobulated chromatin-dense nucleus and 
granules. The granules contain proteolytic and bactericidal substances and can be 
classified as primary or azurophil granules, secondary or specific granules, and 
gelatinase granules or secretory vesicles. Neutrophils are produced by bone marrow and 
are then released into blood circulation, representing more than 50% of leukocytes in 
circulation (33). 
Neutrophils are the first phagocytes to leave circulation and to be recruited to infection 
sites. They can become primary host cells for intracellular pathogens, like Leishmania 
parasites. Leishmania chemotactic factor (LCF) recruits neutrophils to infection site and 
interacts with the chemokine receptor lipoxin A4 receptor (ALX) (12, 39). Neutrophils are 
primary antimicrobial effector cells and destroy invading pathogens by phagocytosis (33). 
Neutrophils are an important link between innate and adaptive immunity during 
parasitic infections. They conduct inflammatory responses and tissue repair, which leads 
to infection control (43). Neutrophils can be recruited by IL-8, IL-17 and tumor necrosis 
factor (TNF). In skin lesions, TNF-α is crucial for inflammation resolution. So, in CL, 
macrophages and neutrophils seem to contribute to parasite clearance and protective 
immunity (12, 44). 
There are 2 different microorganisms recognition mechanism by neutrophil 
granulocytes: opsonin-dependent and opsonin-independent. Opsonins are serum 
components that bind both to microorganisms’ surface and to specific receptors on 
phagocyte’s surface. They can be immunoglobulin (Igs), C3bi fragment or mannan-
binding lectin. Phagocytosis can be mediated by direct recognition of pathogen-
associated molecular patterns via pattern recognition receptors, which is a non-opsonic 
phagocytosis. After phagocytosis, the phagosome and cytosolic granules merge, 
generating the phagolysosome. Then, azurophil granules release hydrolytic enzymes and 
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bactericidal proteins, such as elastase, bactericidal permeability-increasing proteins and 
defensins (33). 
PMN produce highly reactive oxygen species (ROS) (33). Inside phagolysosomes, 
parasites are phagocytized and exposed to enzymes, antimicrobial peptides or ROS. 
Neutrophils use nitric oxide (NO)-dependent and O-independent mechanisms for 
parasites elimination. To kill the pathogen, pre-formed proteinases or antibiotic proteins 
are released. Neutral proteases, such as neutrophil elastases (NEs) activate infected 
macrophages, in order to eliminate Leishmania parasites via toll-like receptor (TLR) 4 
signaling. L. major block oxidative burst and evade elimination, and L. donovani is not 
found inside lytic compartments (39). PMN cells kill most ingested microorganisms. 
However, some can survive. This unexpected survival can be explained by escape from 
lytic compartments, blockade of phagosome-lysosome fusion or inhibition of oxidative 
burst induction (12, 33). 
Leishmania is phagocytized by neutrophils in an opsonin-independent manner. This 
uptake does not activate oxidative burst, so parasites survive inside neutrophils. They are 
phagocytized silently (33). 
Interferon (IFN) γ is a potent and critical modulator of PMN, regulating differential 
gene expression, ROS production, and surface markers expression, such as CD69 and 
Fc-γ-receptors (Fc-γ R). IFN-γ enhances bactericidal activity. L. major inhibits IFN-γ-
signaling in PMN, which is a common evasion mechanism for intracellular pathogens. As 
a result, Leishmania compromises host cells IFN-γ-signaling, a potent inhibitory 
mechanism by which cellular activation is suppressed in macrophages and in neutrophils 
(33). 
Comparing to macrophages, neutrophils are short-living cells. Their half-life ranges 
from 6 to 10 hours. Then, they undergo rapid spontaneous apoptosis, leading to their 
phagocytosis by macrophages (12). Apoptotic neutrophils show shrinkage, chromatin 
condensation, and loss of nucleus multilobed shape. Cell surface shows decreased 
expression of some receptors or new surface molecules. Neutrophils constitutively 
express the pro-apoptotic proteins Bax, Bid, Bak, and Bad. The anti-apoptotic Mcl-1 
protein is expressed in bloodstream neutrophils and its levels decrease prior to apoptosis 
onset (33). Infection can increase their half-life in several days. For human neutrophils in 
vitro infection with L. major, their half-life is prolonged in 2 days, inhibiting procaspases 
processing (12). 
Viable Leishmania parasites delay PMN cells apoptosis. Pro-inflammatory cytokines, 
such as TNF-α, IL-15, IFN-γ, granulocyte colony-stimulating factor (G-CSF), granulocyte 
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macrophage colony-stimulating factor (GM-CSF) and IL-8 delay neutrophils’ apoptosis. 
IL-8 targets neutrophils, and creates an autocrine feedback loop that recruits more 
neutrophils to infection site, delaying apoptosis (33). 
Senescent neutrophils are removed from blood circulation and replaced by mature 
ones. At local sites of infection or inflammation, it is very important how recruited 
neutrophils are removed from the inflamed spot. In Leishmania infection, the apoptotic 
neutrophils externalize PS, which facilitates recognition and silent clearance of apoptotic 
neutrophils by macrophages. Leishmania delays PMN apoptotic death up to 2 days. 
Infected PMN secrete high levels of macrophage inflammatory protein (MIP) 1b, which 
attracts macrophages. This secretion coincides with macrophages migration peak into the 
infected tissue. Macrophages phagocytize infected apoptotic PMN. Apoptotic cells 
clearance is a major macrophage function. Though ingestion of apoptotic cells, in general, 
does not result in the activation of antimicrobial effector functions. Phagocytosis of 
apoptotic neutrophils deactivates phagocyte functions, and no significant amounts of TNF 
are released. Intracellular parasites inside PMN do not have direct physical interaction 
with macrophages surface receptors. So, there is no macrophages activation (33). 
Neutrophils move rapidly to infection site, but become 80% slower after phagocytosis. 
There can be parasite release before apoptosis (39). 
Apoptotic neutrophils are a temporary shelter for Leishmania parasites. For this, they 
are called “Trojan horses” (33, 39). This increases silent uptake of Leishmania and a 
higher level of survival inside the macrophage. Neutrophils conversion into “Trojan 
horses” occurs through the following steps (39) (Figure 4): 
1. Neutrophils are recruited by ALX, and avoid activation of lethal functions. ALX 
activation by lipoxin A4 deactivates oxidative stress, and increases apoptotic cells 
phagocytosis; 
2. Decrease phagocyte machinery for apoptotic cells uptake. PS+ promastigotes 
induce TGF-β production, anti-inflammatory cytokine, and phagocyte functions will 
not be activated; 
3. Apoptotic neutrophils die by apoptosis and recruit macrophages for their own 
phagocytosis. They regulate their silent clearance and, if there is an infection, 
promastigotes transfer will happen. Leishmania infection delays neutrophils 
apoptotic death up to 2 days. Apoptotic neutrophils release MIP-1b, providing a 
migration of macrophages into the infected tissue. There is almost no extracellular 
promastigotes. 
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Figure 4. “Trojan horse” infection model. Depending on Leishmania strain and model used, neutrophils can 
serve as a (A) “Trojan horse” to transfer parasites into macrophages. Leishmania parasites can also hide 
outside the apoptotic neutrophil (B) to get inside the macrophage, “Trojan rabbit”. This is a free adaptation 
from the film “Monty Python and the Holy Grail” (39). 
Recently, a new neutrophil-mediated antibacterial mechanism, the release of 
neutrophil extracellular traps (NETs), has been described. NETs are released by dying 
neutrophils, as well as antimicrobial factors. They are extracellular structures produced by 
stimulated neutrophils. These structures contain DNA, histones, granular proteins and 
antibacterial enzymes that bind and kill infective organisms. This cell death process is 
different from apoptosis and necrosis and depends on the generation of ROS by NADPH 
oxidase (33, 39, 45). 
Macrophages clear apoptotic cells, and maintain tissue homeostasis. Resting 
macrophages phagocytize metacyclic promastigotes, allowing them to differentiate into 
amastigotes (42). When macrophages get infected, they start cell death process and start 
to spread parasites, see Figure 5. Amastigotes replicate extensively before spreading to 
other cells, until their number exceeds the lethal parasite density. Parasite transmission 
occurs when macrophages phagocyte dying primary host cells, such as neutrophils. 
Macrophages are recruited approximately 2 days post-infection (46). 
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Figure 5. Early events in Leishmania infection. (1) Viable and apoptotic promastigotes in Leishmania’s virulent 
inoculum. Viable promastigotes survive inside PMN, due to a “silent entry”. (2) Leishmania infection delays 
neutrophil apoptosis. (3) Monocytes/Macrophages migrate to infection site. (4) Apoptotic infected neutrophils 
are ingested by macrophages. (5) Apoptotic neutrophils’ phagocytosis provides “silent entry” into 
macrophages (33). 
There is a balance between macrophages activation and subpopulations, and 
Leishmania parasites survival mechanisms, which are highly related to their species and 
associated virulence. Leishmania parasites interfere with host cells signal transduction 
pathways, such as transient activation of mitogen-activated protein kinase (MAPK) and 
nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) signaling. L. major 
promastigotes were shown to downmodulate these pathways. Infection with amastigotes 
also modulates MAPK signaling, which can lead to pro-inflammatory signals suppression 
and IL-10 production promotion (28). This will further suppress TNF-α release by infected 
macrophages. Prolonged and repeated interactions between lipopolysaccharide (LPS) 
and macrophages can lead to its tolerance (47). 
Phagocytosis is mediated by Fc and complement receptors, and suppressed by PS 
recognition on apoptotic cells membrane. Apoptotic cells uptake decreases pro-
inflammatory cytokines, such as TNF-α, IL-1, and IL-12 secretion by macrophages. Anti-
inflammatory cytokines production is induced, TGF-β and IL-10, and pro-inflammatory 
cytokines are downregulated, such as TNF-α. PS recognition prevents immune 
responses against internalized and processed apoptotic proteins remains. Cytokine 
production by macrophages is dependent on PS density. PMN cells secretion of TGF-β 
correlates positively with apoptotic parasites ratio. An inverse correlation is observed 
between apoptotic parasites ratio and TNF release. Disease is induced after PS 
recognition and TGF-β production (28, 33, 34). TGF-β prevents immune responses 
against internalized and processed apoptotic proteins, and its neutralization decreases 
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survival inside neutrophils (34). Leishmania parasites assure their survival and prevent 
tissue damaging due to inflammatory processes (42). This is a “silent entry”, because 
infection occurs without maturation induction (28). 
DCs are important for parasite dissemination. DC entry depends on C-type lectin, 
ICAM-3-grabbing non-integrin, as the putative receptor on DC for L. infantum and L. 
pifanoi amastigotes. These molecules are parasite specific, and internalization by these 
receptors does not activate DCs (28). 
Both amastigotes and promastigotes can start an infection. Promastigotes turn into 
amastigotes after 24 to 72 hours. Amastigotes are sustained and kept for days inside 
macrophages, which produce superoxide anion (O2-) to infection with promastigotes and 
produce much less for amastigotes’ infection (28). 
O2- production suppression occurs due to NADPH oxidase enzyme complex inability 
to assemble inside PV, because p47 is not phosphorylated by protein kinase C (PKC), 
which is inhibited by amastigotes and promastigotes. Promastigotes do it through their 
LPG coating (28). Superoxide dismutase (SOD) detoxifies O2-, converting it into H2O2 and 
H2O. The genes SODA and SODB were identified in L. chagasi, and their overexpression 
protects the parasite from oxidative stress burden (48). 
Leishmania infection can block NO production. NO is the product of inducible NO 
synthase (iNOS) gene, which is induced by IFN-γ. For L. amazonensis amastigotes, PS is 
displayed and parasites are internalized via PS receptors on macrophages. After, IL-10 
and TGF-β secretion is induced, and these block iNOS. Therefore, there is no NO 
production (28). 
Zn metalloproteases, and cysteine proteases are also virulence factors (26). Gp63 is 
a metalloprotease that cleaves C3b to C3bi on the parasite’s surface membrane. It is a 
virulence factor for L. major, L. amazonensis, L. mexicana, and L. donovani. So, 
complement mediated lysis is inhibited and parasite uptake by macrophage complement 
receptor (CR) 3 is promoted. Extracellular release of Gp63 facilitates parasite’s 
dissemination through tissue, degrading extracellular matrix components. It also subverts 
immune responses: cleaves major histocompatibility complex (MHC) class I molecules 
and CD4 to limit T cell responses, and downmodulates MARCKS-related (myristoylated 
alanine-rich C kinase substrate) protein. For amastigotes pathogenesis, it is significantly 
downregulated, though its role is still unclear (25). 
LPG is a virulence factor for L. major and L. donovani, but not for L. mexicana (25, 
34). LPG is important for NO production modulation, apoptosis inhibition, phagolysosome 
maturation delay, and macrophage signal transduction inhibition. LPG is the ligand for 
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C3bi deposition on promastigote surface, which is critical for CR3-mediated uptake and 
for inhibiting macrophage IL-12 and NO responses to infection (25). In amastigotes, it is 
minimally expressed, because they express high levels of glycoinositolglycolipids 
(GIPLs), and get other host cell lipids. This lipidic coating helps to avoid macrophages 
activation, and, possibly, to suppress IL-12 production in infected cells, which is 
responsible for immune response initiation (28). 
Fe generates toxic reactive nitrogen intermediate (RNI) and reactive oxygen 
intermediate (ROI). Fe decreases iNOS expression by IFN-γ-activated macrophages, 
promoting pathogen survival. Fe2+ is translocated through Nramp2 into cytosol, and Fe3+ 
is produced. Nramp1 transporter shows up in later endosomes or lysosomes. Leishmania 
parasites compete with host Fe transporters. Fe uptake in L. chagasi occurs preferentially 
in Fe2+ form, which is essential for parasite growth and virulence. Fe3+ reduction is 
coupled to Fe2+ membrane transport by LIT1. LIT1 is a plasma membrane structure 
essential for parasite’s intracellular replication and virulence (48). 
 
3.5 Immunology 
Leishmania infections induce strong humoral responses. Though, antibodies do not 
protect, but are associated with disease (49). Protective immunity is related to a classical 
cell-mediated immune response (25). 
After a primary non-specific innate immune response, a specific T cell response is 
developed and determines disease development (49). This early innate response involves 
TLR2 receptors in macrophages, DCs and nature killer (NK) cells. Macrophages activate 
specific T cells by IFN-γ or TNF-α production (13). Macrophages and DCs are antigen-
presenting cells (APCs) with phagocytosis characteristics (15). DCs promote mixed T cell 
immune response, are present in all lymphoid organs and are essential for immunity 
induction. Special inflammatory DCs, like TNF-α iNOS-producing DCs (TipDC), produce 
TNF-α, NO, IL-12 and stimulate T cells. iNOS production by TipDC is positively regulated 
by T helper (Th) 1 cell response and negatively by Th2 response, see Figure 6. DCs are 
essential in developing Th1 protection. During L. major infection, inflammatory DCs are 
the main iNOS producers. Their recruitment depends upon CCR2 expression, and iNOS 
expression induction requires a local Th1 environment (50). 
Th1 cells mediate a protective immune response, but the identification of a precise 
role for Th2 responses remains yet to be clarified (25). Th1 cells secrete activators of cell-
mediated immunity, such as IFN-γ, while Th2 cells secrete cytokines that promote 
antibody responses, such as IL-4. IL-4 induces Th2 response, and IL-12 induces Th1 
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cells differentiation (49). DCs are IL-12 producers during early infection. CD40–CD40L 
interactions enhance IL-12 production, and mice lacking this pathway are susceptible to 
CL. IL-12 is essential in Th1 responses. 
 
Figure 6. Th1 and Th2 dichotomy in Leishmania infection (49). 
IL-12-driven Th1 response promotes protective immunity against all Leishmania 
species, although DCs are the primary source. IL-12 activates NK cells. NK cells produce 
IFN-γ, which controls innate resistance to infection, and influences Th1 response 
initiation. All resulting IFN-γ from NK cells, CD4+ T and CD8+ T cells, induce macrophages 
NO production (25, 50), providing parasite clearance and healing (12). The failure to 
regulate an effective Th1 immune response can lead to a bad immunological memory 
(11). IL-12 and IFN-γ are protective cytokines (49). IFN-γ-activated macrophages produce 
RNIs, but are inhibited by IL-4, IL-10, IL-13 and TGF-β. This downregulation might be 
crucial for acquired resistance development (51). 
TNF-α is essential for L. major infection resolution. TNF-α enhances macrophage 
activation, NO production and parasite clearance. IFN-α/β is produced by APCs, and can 
activate macrophages, in order to produce NO. IL-12, TNF-α and IFN-α/β can develop a 
protective Th1 response to L. major infection (49). L. major infection control and 
resistance require IL-12 dependent differentiation of CD4+ T cells. Amastigotes and 
promastigotes can subvert macrophages IL-12 production (28). Genetically resistant mice 
strains develop a strong Th1 response and restrict the spread of local parasite infection. 
Non-healing mouse strains have a Th2 response associated with high level of IL-4 and IL-
13 production by CD4+ T cells (50). DCs produce IL-12 during early infection. CD40–
CD40L interactions enhance IL-12 production, and mice lacking this pathway are 
susceptible to CL (49). 
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Th1 responses (Figure 7) and macrophage activation are suppressed by IL-10 and 
TGF-β (49, 51). Genetic suppression of Th1, will lead to susceptibility. IL-12-IL-12R 
signaling is essential to develop a healing Th1 response. NK cells belong to innate 
immune response, participate in Th1 response, and release IFN-γ, which optimizes IL-12 
production by DCs and IL-12R by T cells (6). 
Th2 early response is significant for cytokines production and clinical development 
(51). Th2 response depends on Leishmania species. Th2 cytokines are immunoregulators 
for early infections (49) and secrete IL-4 and IL-13, which cause susceptibility (12). IL-4-
driven Th2 immune response counter-regulates Th1 response and promotes disease 
development. Disease is due to no Th1 response, because of no IL-12 production. IL-4 
cans downregulate IL-12 production, expression of IL-12Rb2, IFN-γ production and 
activity. After primary infection, IL-4 and IL-4Ra signaling are essential for parasite liver 
and spleen infection. IL-4 and IFN-γ activate macrophages against L. major. IL-13 has the 
same signaling pathway as IL-4, and also downregulates macrophage activation. It 
enhances monocyte IL-12 production, induced by IFN-γ, while IL-4 and IL-13 promote 
macrophages and DCs IL-12 production, induced by CD40L. IL-4 and IL-13 can be pro- 
or anti-inflammatory, depending on the extracellular environment (25). They are protective 
cytokines in L. major and L. donovani infections, but not in L. mexicana or L. 
amazonensis infections (49). Susceptibility to L. major, influenced by IL-4 and IL-13, is 
mediated by IL-10. IL-10 has a similar role in susceptibility to VL with L. donovani, and no 
disease exacerbatory role for IL-4 or IL-13 has been reported (25). IL-6 favors Th2 
response (49). 
IL-4 and IL-13 protect against L. major and L. donovani infections, but not for L. 
mexicana or L. amazonensis infections. In L. major early infection, resistant and 
susceptible hosts have mixed Th1 and Th2 responses of CD4+ cell population. During 
early infection stages, IL-4-producing CD4+ T cells population may be important for 
disease progression. IL-4 induction depends on other T cell factors, such as IL-2, which 
may be a susceptibility factor. IL-13 or IL-2 can substitute IL-4 (49). 
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Figure 7. Immune response against Leishmania parasites. Susceptibility or resistance against the disease 
depends on the type of cytokines secreted (13). 
Susceptibility is a multigenetic phenomenon (44). Susceptibility and resistance to 
Leishmania in mouse model are associated with emergence of T cells, T regulatory (Treg) 
cells and cytokines, such as IL-10 (49). In localized human CL, Th1 cells predominate, 
and Th2 immune response markers are detected in DCL or MCL. Cure is associated with 
IFN-γ production and IL-10 with lasting lesions (44). Treatment of non-healing lesions with 
IFN-γ leads to cure. In human VL and DCL, IFN-γ absence allows parasite multiplication 
and disease progression (49). 
The second IFN-γ significant producer is CD4-CD8- T cells, double negative (DN) T 
cells, see Figure 8. DN T cell population contains T cells expressing γ/δ or α/β T cell 
antigen receptor (TCR) complex. α/β TCR+ DN T cells are restricted to CD1 presented 
antigens, which express a restricted TCR and recognize lipid antigens presented by one 
of the CD1 family of molecules. These T cells are classified as invariant NK T cells and 
express a restricted TCR. 80% of peripheral blood DN T cells express γ/δ TCR. α/β DN T 
cells are highly activated T cells. α/β DN T cells express high IFN-γ or TNF-α to IL-10 
ratios after soluble Leishmania antigen (SLA) induction (11). 
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Figure 8. Cytotoxicity. αβ+ DN T cells contribute to a leishmanicidal immune environment while, γδ+ DN T 
cells appear to contribute for a downregulatory environment in human CL, caused by L. braziliensis. The 
overall balance will determine if an immune response is effective. Though, it allows some persistence, which 
is important for long-lasting immunological memory (11). 
CD25+Foxp3+ Treg cells downregulate specific immune responses against the parasite 
and can be linked to chronic progressive disease (13). Treg cells produce TGF-β and IL-
10. Localized immune responses show tissue tropism and localized growth patterns. Treg 
cells suppress effector T cell activity through IL-10 production. Treg cells produce most of 
the IL-10 responsible for chronic infection, and CD25-􏰁T cells produce most of the IFN-γ 
(49). 
In VL patients, IL-12 enhances Th1 immune response and restores T cell proliferation, 
IFN-γ production and cytotoxicity. IL-12 decreases spontaneous or antigen-induced 
peripheral blood mononuclear cells apoptosis in VL patients. IL-12 and Leishmania 
antigen restore proliferation of these cells in VL patients (49). Infection control or 
exacerbation is regulated by IL-10 (Figure 9). CD4+ T cells and monocytes are important 
sources of IL-10. A lower IFN-γ/IL-10 ratio is associated with better L. braziliensis infection 
prognosis (11). IL-10 is important for disease progression, it inhibits IFN-γ and promotes 
parasites persistence (49). It inhibits macrophage activation, and is the major cytokine 
involved in visceralization. IL-10 blocks Th1 activation and promotes a cytotoxic response 
by downregulating IL-12 and IFN-γ production. Active VL has increased production of IFN-
γ, IL-2, IL-10 and IL-4. After cure, IFN-γ, from CD4+ Th1 cells, IL-4 and IL-10 persist, 
suggesting mixed Th1 and Th2 responses in VL and cured individuals (11, 49). IL-12 and 
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IL-10 are critical for immune regulation during infection, pathogenesis and chemotherapy. 
Parasites may start modulating macrophages on early and later infection, on infected 
macrophages with T cells and induce IL-4 and disease-inducing factors from T cells, 
which help in disease and parasite survival. Infected macrophages produce IL-10. IL-10 is 
crucial in disease initiation independent of T cells and in disease progression later with IL-
4 (49). 
A Th1 immune response can lead to non-healing L. amazonensis infection, but not L. 
major infection. L. mexicana complex parasites downregulate Th1 responses by IL-4-
dependent and independent mechanisms. In Th2 immune response, IL-4 and IL-13 
production is associated with chronic infection. IL-10 and TGF-β are important to enhance 
VL development. IL-10 promotes non-healing L. major infections, but is less significant 
during L. mexicana and L. amazonensis infections. B cell mechanisms promote L. 
donovani and L. mexicana complex infections (25). 
The Leishmania homolog of receptor for activated C kinase (LACK) antigen promotes 
IL-4 production through Vβ4+Vα8+CD4+ T cells activation and is crucial for BALB/c mice 
susceptibility by L. major. It is required for parasite persistence within macrophages. In L. 
mexicana parasites complex, cathepsin L-like cysteine protease B (CPB) enzymes are 
considered virulence factors. CPB enzymes induce IL-4 production and Th2 immune 
response. L. mexicana can inhibit macrophage and DC IL-12 production, conditioning 
DCs to produce more IL-4. L. donovani and L. chagasi CPB enzymes activate latent TGF-
β, which is a suppressive cytokine in Leishmania infection. Cathepsin L and B-like CPB 
may inhibit Th1 or promote Th2 response, respectively (25). 
In CanL, gestation maintenance depends on the development of an immunoregulatory 
response. Th2 immune response is amplified and there is an increase in TGF-β, IL-6 and 
IL-10 release. Th1 response is depleted, with reduced production of abortive pro-
inflammatory cytokines, such as INF-γ and TNF-α. TNF-α and INF-γ induce amastigotes’ 
death in CanL. In pregnant dogs, polarization of Th2 response can increase parasite load 
(10). 
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Figure 9. Immunological responses to L. major (49). 
B cell-derived antibodies are important for adaptive immune responses. Antigen-
specific IgG and natural IgG are responsible for opsonization (44). The role of B cells and 
antibodies in susceptibility depends on the Leishmania species and virulence factors. 
Downregulation of MHC class II presentation is normal, when parasites destroy it within 
PVs. Without antibodies, parasite uptake does not activate DCs and silent infection phase 
initiates. The role of antibody in pathogenesis mediates parasite uptake and regulates 
CD4+ T cell activation and immune response at the local cutaneous site of infection. 
Nevertheless, systemic immune response to infection is not affected by antibody’s 
absence. Though, a local immune response promotes parasite intracellular survival (25). 
Extracellular pathogens replicate outside the host cell, controlled by non-opsonic or 
opsonic phagocytosis. Th cells support neutrophils and macrophages by stimulating B 
cells, in order to produce antibodies and promote abscesses formation (40). 
Leishmania species interactions with host cells are summarized on Table 3. 
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Table 3. Leishmania species-host interactions (50). 
  L. major L. donovani L. mexicana              L. amazonensis 
Th1 relevance for cure + + + 
IL-12 resistance induction + + - 
B cells in pathogenesis Dose dependent Ab independent Ab dependent 
T cell deficient mice pathology + + - 
Virulence factors    
LACK + Unknown - 
LPG + + - 
A2 - + Unknown 
Cysteine protease - Cathepsin B-like Cathepsin L-like 
Disease    
IL-4 Strain dependent - Host/Site dependent 
IL-10 + + Somewhat 
CD4 and CD8 T cells, NKs, and NK T cells mediate cytotoxic immune responses (13). 
CD4+ and CD8+ T cells are important for acquired resistance, sustained IL-12 production 
and parasite persistence (51). CD8+ T cells develop immune memory and are involved in 
primary infection clearance (49). Cytotoxic mechanisms involve antigen-dependent or 
independent apoptosis of targeted cells (13), see Figure 10. 
CD8 T cells produce IL-2, IL-4, IL-5, IL-10, IFN-γ, TNF-α and TGF-β. Two types of 
CD8 T cells have been proposed, T cytoxicity (Tc) 1 and Tc2 cells, depending on their 
cytokine production profile and migration ability (13). Tc cells release IFN-γ. IL-12 can 
induce Th1 and Tc1 cells responses (44). Cytotoxicity can then occur by lytic granules 
release, like perforin, and membrane expression of FasL/CD95L, which initiates apoptosis 
by caspase 8 activation. CD8 T cell response initiates when specific antigens presented 
by MHC class I molecules are recognized, in association with co-stimulatory signals on 
APCs. To become fully activated, they need CD4 T and DCs. DCs present antigens to 
CD4 T cells by MHC class II molecules, leading them to clonal expansion and 
differentiation, which upregulates CD40L expression. This interacts with CD40L, 
activating CD8 T cells that will further recognize MHC class I. If this does not happen, 
cells will not express CD40 and tolerance will occur. CD8 T cells have been associated to 
tissue damage. CD8 T cell activation through cross-presentation of apoptotic cells by DC 
can lead to immunity. CD4 T cells mainly regulate IFN-γ production. For L. braziliensis 
infection, the acute phase presents more CD4 T cells. During healing, CD8 T cells 
increase number until equilibrium. For L. braziliensis, CD8 T cells are also involved in 
chronicity and exacerbated tissue lesions (13). 
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HIV infected patients have lower CD4 levels, so leishmaniasis exacerbation can be 
seen (44). In macrophages, Leishmania parasites increase HIV-1 gene transcription and 
release of progeny virus, enhancing the production of pro-inflammatory cytokines. 
Amastigotes increase IL-6 and TNF-α production, which leads to higher viral replication 
(15). 
 
Figure 10. CD8 T cell activation by cross-presentation. iDC – Immature DC, mDC – Mature DC (13). 
Leishmania species parasites are able to cause mice disease. This is a useful mean 
to study intracellular parasitism. However, its greatest value was the aid to understand the 
biochemical pathways responsible for Th1/Th2 immune responses dichotomy (25), see 
Table 4. 
BALB/c mice do not control infection; they develop lesions and systemic disease. 
They are the animal model for non-healing human disease (51). BALB/c mice develop a 
typical Th2 immune response (49). Genetic susceptibility is related to IL-4 and IL-2 Th2 
response, which causes disease. Th1 response releases IFN-γ, which leads to parasite 
clearance. In BALB/c mice infected by L. major, IL-12 drives to Th2 response and 
promotes resistance. Downregulation of IL-12 upregulates IL-4 production, which leads to 
disease. So, anti-IL-12 antibodies will exacerbate disease. Inoculation site might also 
influence T cell response, and DC subpopulations are able to induce Th1 or Th2 cells 
priming (51). Targeted disruption of IL-4 gene in BALB/c mice leads to high resistance, 
while IFN-γ and IL-4 gene disruption in C57BL/6 mice turns them into susceptible models 
(49). In BALB/c mice, LACK antigen induces IL-4 production by Vβ4+Vα8+CD4+ T cells, 
which renders T cells resistance to IL-12 and leads to lesion development. Tolerance to 
LACK gives an enhanced Th1 response, a diminished Th2 response, and healing. IL-10 
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derived from CD4+CD25+ Treg cells is responsible for maintaining latent infection in 
resistant mice, and ensuring long-lasting immunity (25). Neutrophil depletion leads to 
increased parasite elimination (43). 
C57BL16 mice have localized dermal lesions that heal spontaneously. Healing is 
associated with immune activation of infected macrophages and parasites killing (52). 
Th1 response to infection does not eradicate all parasites, but provides cellular 
recruitment and parasite replication. Infection of T cell-deficient C57BL/6 mice with L. 
major or L. donovani is associated with parasite multiplication, dissemination, and disease 
exacerbation. L. amazonensis infection shows small lesions and low parasite levels. 
When L. amazonensis-infected mice are reconstituted with CD4+ T cells, lesion 
development is restored. So, CD4+ T cells contribute to susceptibility. For L. major, 
recruitment of macrophages occurs without T cells. L. amazonensis persistence in Th1 
response is essential for macrophage activation, and macrophage recruitment is required 
for parasite survival and persistence (25). 
L. mexicana and L. amazonensis produce chronic infections in most mice strains. IL-4 
is crucial for initial L. mexicana lesion development, and chronic infection maintenance 
requires IL-4 and IL-13. For L. amazonensis, inhibition of IL-12Rb2 expression, 
independent of IL-4, is the main mechanism preventing Th1 response development and 
healing. There is a disease-promoting role for IL-13 during infection with both species. For 
L. donovani, protective immunity depends on an IL-12-driven Th1 response and IFN-γ 
production, which kills parasites by ROI and RNI production. Human VL shows a cytokine 
profile of mixed Th1/Th2 characteristics. IL-12 promotes Th2 and Th1 immune responses. 
IL-10 is the major immunosuppressive cytokine in VL. Neither IL-4 nor IL-13 exacerbates 
disease during VL. IL-10 has been suggested to be as important as IL-4 and IL-13 for L. 
major susceptibility (25). 
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Table 4. Genetic differences in phagocyte behavior in CL (44). 
  BALB/c C57BL/6 
Neutrophils +++ + 
 Persisting infiltration  
 Depletion >  Disease Depletion >  Disease 
 Interaction of infected macrophages with apoptotic neutrophils 
  TGF-β + PGE2 > Parasite persistance TNF-α > Parasite killing 
Macrophages Less mature (MRP14+) More mature (F4/80+) 
  Killing efficiency  Killing efficiency 
   IL-12 release  IL-12 
DC  IL-1α/β  IL-1α/β 
 IL-12p70 IL-12p70 
  IL-12p40  IL-12p40 
  IL-12p80  IL-12p80 
  Unknown IL-27 
According to Stebut (2007), immune response against Leishmania parasites can be 
summarized into 4 distinct phases, see Figure 11: 
1. Leishmania parasites activate complement system, and the parasite gets 
opsonized with C3bi and C3b. C3 breakdown attracts neutrophils. However, 
promastigotes are resistant to complement lysis. The CR3 provides Leishmania 
parasites entry into macrophages. This is a silent process and inhibits IL-12 
synthesis pathway. This early phase of infection lasts for 4 to 5 weeks, without 
visible clinical skin affection. During this period, parasites differentiate into 
amastigotes that will induce macrophages rupture; 
2. Innate immune system is activated. Skin lesions develop, and inflammatory cells 
are called to infection site, such as neutrophils, eosinophils, or macrophages. 
Macrophages induce proinflammatory cells recruitment, such as neutrophils, 
eosinophils, mast cells (MCs), and are involved in granuloma formation. TNF-α 
release from MCs promote neutrophil influx, which will further release MIP-1α/β 
and MIP-2, in order to recruit more macrophages. Neutrophils participate in 
granuloma formation and help to create protective immunity; 
3. DCs CD4+ and CD8+ T cells migrate at the same time. DCs phagocytize 
amastigotes through Fc-γ R III and I. Induction of adaptive T cell responses by DCs 
in skin links innate to adaptive immunity. Infected macrophages and DCs, which 
are APCs, present Leishmania antigens to primed T cells, which can be primed by 
CD4+ or CD8+ T cells. Activated DCs are the only cells able to present both in MHC 
class II and I. Macrophages express low levels of MHC class II and co-stimulatory 
molecules and are unable to prime T cells. Phagocytosis mediated by Fc-γ R leads 
to Leishmania antigen presentation in MHC class I to CD8 T cells, and CR3-
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mediated phagocytosis by macrophages leads to MHC class II presentation. DCs 
can induce Th1 or Th2 immune responses; it just depends on extracellular 
environment. In cutaneous infections, DCs preferentially induce Th1/Tc1 immunity. 
IL-12 family, such as IL-27 or IL-23, and IL-1 contribute to induce and maintain Th1 
responses; 
4. Infection control does not mean complete parasite clearance. Persisting parasites 
contribute to immunity perpetuation. Antigen persistence is important for T cell 
memory maintenance. Both effector memory T cells residing on skin and long life 
central memory T cells in lymph nodes require remaining parasites. Fc-γ R 
activation on infected macrophages induces IL-10 release, which prevents parasite 
elimination and promotes disease progression. 
 
 
Figure 11. Immunological status in Leishmania infection. Lesion resolution coincides with DC infection and 
activation of T cells. Lesion development occurs when inflammatory cells are recruited to infection site. Later, 
lesion resolution is induced by DC-dependent recruitment of antigen-specifically primed T cells capable of 
producing IFN-γ (44). 
Vaccination 
Vaccination seems to be the better method for human disease eradication (21). If 
cured, a primary infection can provide protection against another infection. So, 
theoretically it is possible to produce a vaccine against Leishmania (53). Several 
vaccination strategies have been tested and a number of vaccine trials have been 
initiated without successful results (23). There are still no effective human vaccines yet. 
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Leishmania vaccination seems possible, because only a small percentage of 
individuals develop active disease in endemic areas and successfully cured patients 
rarely get re-infected. Many vaccination strategies have been tested for CL caused by L. 
major. Less effort has been done for VL, with attenuated or killed parasites, crude antigen 
fractions, purified L. donovani membrane proteins and DNA vaccines. Few vaccines have 
succeeded to reach phase I trials (49). 
Th1 and Th2 immune response dichotomy for antigen selection in vaccine 
development has been used. Leishmania antigens that stimulate Th1 responses are 
regarded as potential protective antigens and promising future vaccines. Antigens that 
stimulate Th2 response are not interesting vaccine candidates, due to their possible 
relation with disease. Th1 response induction may not be protective, and should not be 
used alone for antigen selection (49), see Figure 12. 
 
 
Figure 12. Th1 and Th2 paradigm in vaccine against leishmaniasis (49). 
Live vaccination consists on virulent parasites inoculation in the arm and virtually 
provides complete and life-long immunization (51). Innate immune system modulation 
may be a valuable therapeutic approach, providing long-lasting immune protection. 
According to this approach, some vaccines use infected DCs or DCs loaded with antigen, 
and these are effective against leishmaniasis (44). 
Non-living or protein-based vaccines promote poor CD8+ T cell response and are less 
potent and lasting than live vaccines (51). Vaccination against L. amazonensis or L. 
mexicana depends on CD4+, CD8+ T cells and IFN-γ levels. Vaccines against New World 
species need to maintain a high-level immune response (25). 
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Currently, there are only 2 vaccines (1 live and 1 killed) licensed for human 
leishmaniasis, and 1 for canine prophylaxis. Anti-Leishmania vaccination can be based on 
live vaccines, vaccines with recombinant viruses and bacteria as delivery vehicles, 
vaccines based on purified Leishmania antigens, vaccines based on recombinant or on 
sandfly salivary antigens, or synthetic vaccines. The most promising vaccination strategy 
relies on vaccines composed of complex native antigens and well adjusted and 
developed adjuvants (54). 
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1. Current Therapy 
All leishmaniasis disease form has the same point in common. After infection by 
promastigotes, as explained on the previous chapter, these will be phagocytized and 
differentiate into amastigote form. Amastigotes are the ones who perpetuate infection 
and, eventually, lead to host cell death. This is why amastigotes must be considered the 
chemotherapy target. 
Amastigotes and promastigotes have different morphology and biochemistry, which 
explains different drug sensitivity levels. The amastigote multiplies inside the macrophage 
phagolysosome, where pH is from 4.5 to 5.0. So, the molecular weight and pKa of a 
molecule will affect its phagosomal accumulation. It also must be reminded that different 
species of Leishmania inhabit different phagosomes (55), reside in different macrophage 
types, and have different adaptation mechanisms (56). Therefore, it is expected that one 
drug or drug formulation could show different efficacy against the species and clinical 
manifestations leishmaniasis. VL and CL infection sites have different pharmacokinetics 
(PK), and infective species have different drug sensitivity (18). 
Pentavalent antimonials are the recommended drug for VL and CL, and were 
introduced 60 years ago. Over the past two decades few alternative drugs or new 
formulations of old ones became available (57). The few drugs available are expensive, 
toxic, and most of them require IV administration. Because of these adversities, patients 
often do not complete the treatment, enhancing the chances of drug resistance 
development (18). Drug combinations can help to delay or prevent the emergence of 
resistance, increasing efficacy, or shortening the course of treatment (57). 
CL can be treated intralesionally with antimonials, and antiseptics should be applied 
only if the ulcer is infected. Under other circumstances, all lesions should be treated 
systemically. VL is usually treated with injectable drugs, or with oral drugs, such as 
miltefosine. Generally, the injectable drugs are toxic and it is necessary to monitor the 
patient. Cure happens if, 6 months after chemotherapy, there is no fever nor 
splenomegaly (18). Table 5 summarizes current leishmaniasis therapy. 
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Table 5. Leishmania’s current therapy schemes (7). 
Visceral       
Drugs of choice  Liposomal AmpB 3 mg/kg/d IV 1-5, 14 and 21 
 OR SSG 20 mg/kg/d IV or IM x 28 d 
  OR Miltefosine 2.5 mg/kg/d PO (max 150 mg/d) x 28 d 
Alternatives  Meglumine antimonate 20 mg/kg/d IV or IM x 28 d 
 OR AmpB 1 mg/kg IV daily x 15-20 d or every second day for up to 8 wks 
 OR PM 15 mg/kg/d IM x 21 d 
    
Cutaneous       
Drugs of choice  SSG 20 mg/kg/d IV or IM x 20 d 
 OR Meglumine antimonate 20 mg/kg/d IV or IM x 20 d 
  OR Miltefosine 2.5 mg/kg/d PO (max 150 mg/d) x 28 d 
Alternatives  PM Topically 2x/d x 10-20 d 
 OR Pentamidine 
   
2-3 mg/kg IV or IM daily or every second day x 4-7 
doses 
    
Mucosal       
Drugs of choice  SSG 20 mg/kg/d IV or IM x 28 d 
 OR Meglumine antimonate 20 mg/kg/d IV or IM x 28 d 
 OR AmpB 0.5-1 mg/kg IV daily or every second day for up to 8 wks 
  OR Miltefosine 2.5 mg/kg/d PO (max 150 mg/d) x 28 d 
 
1.1 Pentavalent antimonials 
The pentavalent antimonials, see Figure 13, (meglumine antimoniate (Glucantime) 
and sodium stibogluconate (Pentostam, SSG) have variable efficacy against VL and CL, 
require parenteral administration, and are highly toxic. Antimonials should not be used in 
elder patients, in individuals with cardiac and renal disease and during pregnancy (58). 
The emergence of antimony resistance has jeopardized the treatment of VL in many 
countries, such as India (18). Variation in the clinical response is common (59). 
Antimonials are rapidly absorbed and excreted, and their half-life is around 2 hours (55). 
 
Figure 13. Sodium Stibogluconate (SSG) (18). 
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The mechanism of action of antimonials is still uncertain. However, they compromise 
the thiol redox potential of the cell by inducing the efflux of intracellular thiols and 
inhibiting trypanothione reductase (TR). Pentavalent antimony (SbV) enters the host cell, 
crosses the phagolysosomal membrane and acts against amastigotes. It is also likely that 
SbV is also converted to trivalent antimony (SbIII). Glutathione (GSH), glycylcysteine and 
trypanothione reduce SbV non-enzymatically under acidic conditions. Thiol dependent 
reductase 1 (TDR1) and arsenate reductase 2 (ACR2) catalyze the reduction, and ACR2 
increases the sensitivity of Leishmania to SbV. SbV impairs energy metabolism, by 
inhibiting glycolysis and fatty acid oxidation (53, 59). SSG is a potent inhibitor of protein 
tyrosine phosphatases, which leads to increased levels of cytokines. So, SbV may kill the 
parasites by direct and indirect mechanisms, with the host response essential for SbV 
activity. SbIII and SbV have also shown to mediate DNA fragmentation in Leishmania, 
suggesting an induced apoptosis (59). 
Now, antimonials are almost obsolete in India because of drug resistance. 
Nevertheless, they are still useful in the rest of the world, where generic brands lowered 
the prices (60), though resistance has started to be reported (58). The failure of clinical 
response results from acquired resistance and strains with low antimonials sensitivity. 
The inadequate treatment by unqualified personnel, the inability to follow WHO 
guidelines, or the use of poor quality drugs are some of the reasons for the increasing 
treatment failure (18).  
SbIII and SbV routes of entry of in Leishmania are different. SbIII resistance can result 
from reduced uptake or increased efflux (53, 61, 62). Infection with Sb-resistant L. 
donovani induces the upregulation of multidrug resistance-associated protein 1 (MRP1) 
and permeability glycoprotein (P-Gp), avoiding antimonials accumulation. The inhibition of 
MRP1 and P-Gp leads to antimony accumulation and parasite killing within macrophages. 
Unresponsive VL patients overexpress P-Gp and MRP1 (63). At least 2 transporters of 
the ABCC family appear to be involved in antimony resistance: PGPA (MRPA) by gene 
transfection and the proline rich protein 1 (PRP1). Also, total thiols increase happens in 
metal-resistant Leishmania, due to overexpression or amplification of genes involved in 
trypanothione synthesis (53, 61, 62). Antimonials also inhibit DNA topoisomerase I (64). 
Antimonials are cardio and embriotoxic (18). They can induce abdominal pain, 
anorexia, vomiting, nausea, myalgia, arthralgia, headache, malaise, T-wave inversion and 
prolonged QT interval (58). Drug hypersensitivity syndrome, drug reaction with 
eosinophilia and systemic symptoms, and thrombocytopenia induced by parenteral 
meglumine antimoniate were reported (65, 66). As was told before, SSG influences the 
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immune response which can explain the occurrence of PKDL after antimonial treatment 
(67). 
 
1.2 Amphotericin B (AmpB) 
AmpB deoxycholate, see Figure 14, (Fungizones) is an alternative drug for VL and it 
is produced by Streptomyces nodosus. It has been used as first line drug, due to the 
increasing resistance to antimonials. AmpB is as a systemic anti-fungal and a highly 
active antileishmanial. It is a highly toxic drug, so it requires careful and slow intravenous 
administration. Lipid AmpB formulations have been developed in order to improve the 
toxicokinetics and PK drug properties (18). 
 
 
Figure 14. Amphotericin B (AmpB) (18). 
In biological membranes, AmpB complexes with 24-substituted sterols, like ergosterol. 
These complexes open pores which alter ion balance and lead to cell death (56). 
Relapses after treatment can happen, mainly in HIV-positive patients, and resistance has 
already been induced in vitro by gene amplification. Also, membrane fluidity can be 
altered, which decreases binding affinity of AmpB (53). 
Liposomal AmpB formulations, AmBisomes, are an approved treatment of VL. 
AmBisomes have reduced toxicity, better half-life, and high level of efficacy in VL 
treatment, with 90% cure rate. The main limitation is its high cost. Lesser expensive 
AmpB lipid formulations have also been used, but are less efficient and have higher 
toxicity. These novel AmpB formulations have been successfully used to treat CL in 
immunocompromised patients and children (68). In experimental VL models, AmBisome 
has hepatic accumulation, and reaches therapeutic levels faster than antimonials. It also 
has a longer half-life (69). These new formulations can lead to the emergence of 
resistance because of their longer half-lives, as reviewed by Croft and collaborators (59). 
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1.3 Miltefosine 
Miltefosine (Figure 15) was first developed as an anticancer drug. Today, it is the first 
effective oral treatment for VL and the most recent antileishmanial drug to enter the 
market, being also an alternative treatment for HIV patients. Its oral administration 
provides a good PK profile (70, 71), facilitating treatment access, with low costs to health 
sector without the need of hospitalization. Nevertheless, the uncontrolled use of this drug 
can lead to toxicity and resistance events (72). 
The major limitation in miltefosine use is its teratogenicity. Women of child-bearing 
age must take anticonceptionals during the treatment and for more 2 months (18). Also, 
there is a case report of PKDL developed after successful treatment of VL with miltefosine 
(73, 74). It has also shown to induce severe thrombocytopenia (66). 
Miltefosine is effective and well tolerated in VL therapy. It can be recommended as the 
first line drug for childhood VL (75). The combination of miltefosine and AmpB or 
paromomycin (PM) is better than miltefosine and SSG (76). This could be helpful to treat 
antimony-resistant VL infections in India. Considering toxicity and cost, PM is the best 
option (57). 
 
Figure 15. Miltefosine (18). 
Miltefosine impairs the alkyl-lipid metabolism, and phospholipid biosynthesis (53). In 
promastigotes it induces an apoptosis-like cell death. Miltefosine stimulates the 
hematopoietic and immune system, leading to T cells, macrophage and IFN-γ activation 
(70). Miltefosine also promotes p38MAP kinase-dependent antileishmanial functions and 
IL-12-dependent Th1 response (77). 
Due to its long half-life (120 hours) and uncontrolled accessibility, the emergence of 
resistance might become an issue. The combination with other drugs will help to avoid 
this. In vitro studies show that resistance is related to 2 point mutations on an 
aminophospholipid translocase, LdMT, and that miltefosine-resistant clones can be 
readily selected (18, 53, 78). Possible resistance mechanisms already described are: 
reduced drug uptake, impaired membrane permeability, faster metabolism and increased 
drug efflux. Multidrug-resistant L. tropica lines overexpressing P-Gp are less sensitive to 
miltefosine (59). Multidrug resistance 1(MDR1) gene may also be implicated (53). 
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1.4 Paromomycin (PM) 
PM (Figure 16) is an aminoglycoside antibiotic with antileishmanial activity, and is 
produced by Streptomyces rimosus (79). This molecule is highly hydrophilic, has high 
molecular weight, and is relatively lipid insoluble (80). PM is used as a topical treatment 
for CL and as a parenteral drug for VL (60). For CL treatment, liposomal formulations 
have been developed (80). This molecule is off-patent and has received Orphan Drug 
status by US Food and Drug Administration (FDA) and the European Medicines Agency 
(EMEA) (18). 
 
Figure 16. Paromomycin (PM) (18). 
PM impairs the mitochondrial membrane potential, interacts with ribosomes, inhibiting 
protein synthesis, and leads to respiratory dysfunction. PM also alters membrane fluidity, 
lipid metabolism, and mitochondrial function (81). 
PM has not been used extensively, so resistance is not a problem yet (53, 56). But at 
least 3 possible mechanisms of resistance are already known: reduced uptake or 
decreased cell permeability changes at the ribosomal binding sites, or production of PM 
modifying enzymes. PM does not induce cross-resistance (81). 
 
1.5 Pentamidine 
Pentamidine (Figure 17) has been used as second-line drug in the treatment of 
antimony-resistant VL. Pentamidine causes some toxicity, such as hypotension, 
hypoglycaemia, diabetes, and nephrotoxicity. In fact, its toxicity has led to its complete 
abandonment in India. However, this compound can still be valuable for combined 
therapies (53). 
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The cellular target of pentamidine is unknown, but it seems to bind to kinetoplast 
DNA. Resistance to pentamidine has been induced in vitro in several species, and it has 
been related to changes in intracellular concentrations of arginine and polyamines (56). In 
vitro pentamidine-resistant mutants are not able to accumulate pentamidine in the 
mitochondria and the drug is effluxed, by, possibly, PRP1 (53). 
 
Figure 17. Pentamidine (18). 
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2. Future Therapy 
In the last decades, the drug development of antileishmanials has not been a real 
purpose. The few advances done were limited to reformulation of already existing drugs 
and molecular screening, instead of rational design and immunology comprehension. 
New approaches led to novel compounds and molecular targets (60). 
New ideal antileishmanial drugs must be active against CL (topical formulations) and 
VL (oral treatment), have a short period of treatment (less than 14 days), and have a 
single daily dose, have reduced IV treatment time, have lower toxicity, be safe for children 
and pregnant women, have lower cost, have robust formulations, and be suitable for 
combination with existing agents (82). Below, there are some examples of the most 
promising drugs being currently evaluated in clinical trials. 
 
2.1 In clinical trials 
Sitamaquine 
Sitamaquine (Figure 18) is an oral 8-aminoquinoline, and little is known about its 
mechanism of action or resistance (18). Sitamaquine is a lipophilic weak base, which is 
rapidly metabolized, forming desethyl- and 4-CH2OH derivatives that might retain its 
activity. Toxicity appears to be low, but it can cause mild methaemoglobinaemia and 
hemolysis. Sitamaquine seems to affect the electron transport chain (53, 56, 83). Another 
purposed mechanism of action is related to sitamaquine’s fast accumulation in acidic 
compartments, such as acidocalcisomes. These vacuoles are involved in polyP and Ca 
storage, pH homeostasis and osmoregulation. Acidocalcisomes accumulation is different 
between species (84). 
 
Figure 18. Sitamaquine (59). 
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Imiquimod 
Imiquimod is an immunomodulatory imidazoquinoline used for the topical treatment of 
human papillomavirus. It is a potent inducer of IFN-α, TNF-α, IL-1β, IL-6, IL-8, cytoquines, 
and NO. Its target cells are monocytes and macrophages (85, 86). Imiquimod has been 
combined with antimonials to treat patients with CL, which were antimony-unresponsive. 
Alone, imiquimod is not effective as a topical agent (18, 78). The topical treatment 
activates localized macrophages, while the antimonial eliminates systemic amastigotes, 
which are responsible for infection persistence (78). 
Allopurinol 
Allopurinol is a purine analogue and is used as substrate by enzymes of 
trypanosomatids purine salvage pathway. It is selectively incorporated into nucleotide 
intermediates and nucleic acids in parasites. Because of its oral bioavailability and wide 
use for other clinical indications, clinical trials for VL and CL were already started. 
However, the results were not good. Right now, allopurinol is used as maintenance 
therapy in CanL (56). 
Azoles 
Azoles are antifungic drugs. Leishmania produces 24-substituted sterols, such as 
ergosterol. Azoles inhibit 14α-demethylase, a main enzyme in this biosynthesis pathway. 
Ketoconazole, itraconazole and fluconazole (N-substituted) have been submitted to 
several trials for CL and VL, but the results were equivocal (56, 87). Metronidazole and N-
substituted azoles are well tolerated, and are useful in combination therapies (87). 
Bisphosphonates 
Bisphosphonates, such as risedronate and pamidronate, are used in bone disorders 
treatment. They have also shown activity against VL and CL in experimental models. 
Bisphosphonates accumulate in tissues susceptible to infection, are immunomodulatory, 
and are not toxic. They inhibit L. donovani promastigotes and amastigotes’ proliferation 
(88). Bisphosphonates interfere with pyrophosphate metabolism, and the prime target 
might be farnesyl pyrophosphate synthase (FPPS) (56). In BALB/c mice, risedronate is 
effective for VL and pamidronate for CL. Overexpression of farnesyl diphosphate 
synthase was already identified as mechanism of resistance (89). 
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 IV – Drug Discovery 
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1.  Drug Discovery 
Product development partnerships (PDPs) are non-profit companies focused on drug 
development for neglected diseases. PDPs manage new-product portfolios, preclinical 
and clinical development, decisions and clinical trials in developing countries. They 
manage R&D activities through partnerships with industry, and contract research 
organizations and academic groups. Some PDPs have R&D in their laboratories and 
manage major programs. Others mix these models. New drugs pipeline is not enough for 
most neglected diseases. Small-molecule discovery platforms should be available to 
create new hits and leads (3). The development of non-patentable drugs can make drug 
candidates available to anyone who wants to develop them. So, prices can be reduced. 
There are successful historical precedents for private companies developing drugs off 
patent, for instance, polio vaccines (4). Big pharmaceutical companies are placing early 
drug discovery in academic institutions, mainly for non-profitable diseases, such as rare 
genetic disorders and neglected diseases (90). 
Private donors are providing a new generation of drugs for neglected diseases, such 
as the Institute for One World Health, from Bill & Melinda Gates Foundation, and the 
Drugs for Neglected Diseases initiative (DNDi). These donors are non-profit 
organizations, which gather resources for R&D, and act as virtual drug development 
industries. They manage the project and coordinate R&D funds. The aim is to create a 
robust pharmaceutical pipeline with new products registered every few years. Initially, 
known molecules with promising data in target diseases are acquired or new formulations 
or fixed-dose combinations are created. This synergistic approach has already produced 
new drugs for VL. Because many screening projects must be done simultaneously, there 
can be target overlap (3). 
The DNDi was created in 2003. It is a non-profit Swiss foundation. Its partners are 
institutions from developed and developing countries, but the main is Médecins sans 
Frontières. DNDi goals are to develop new drugs for neglected diseases and transfer new 
technology (91). To identify opportunities in R&D, DNDi sends out calls for letters of 
interest to the scientific community. DNDi’s portfolio currently has 9 projects at different 
stages of development for VL, sleeping sickness, Chagas disease and malaria (4). At 
discovery stage, DNDi is working on validating the kinetoplastid enzyme dihydrofolate 
reductase (DHFR) as a potential target for trypanosomatids, and on identifying inhibitors 
of the kinetoplastid enzymes TR and protein farnesyl transferase. At Institut Pasteur 
Korea (IPK), HTS on whole trypanosome cells is being made, in order to discover new 
lead compounds (92). 
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Several developments improved the ability to discover drugs for neglected diseases, 
such as genome sequencing, protein structures determination, compound libraries, and 
bioinformatics analysis (93). 
Globally, there has been a decline in number of drugs against new therapeutical 
targets. Mainly, because of their low clinical success (94). Also, the regulatory authorities 
have been hampering the preclinical development. More sensitive biomarkers are needed 
to facilitate PK and toxicokinetics determination of new molecules (95). The FDA has 
been adopting higher drug approval standards, and is currently requesting extremely 
detailed safety data. This, will prolong clinical trials, increase costs and lower the chances 
of approving a new drug. So, pharmaceutical industry is maximizing sales from the most 
popular drugs by approving new formulations, adding indications and, when patent loss is 
close, follow-on compounds (96). These limitations to drug development led to a lack of 
new molecules which coincides with the development of combinatorial chemistry and HTS 
(95). 
Little development has been made in antileishmania drug discovery. Many of the 
drugs currently used in therapy were developed for other purposes, and their 
antileishmanial use is just an extension of label indications (97). Drug development is very 
expensive, and resources available for antileishmanial research are sparse (56). So, 
rational development is useful, since it lowers the cost of drug discovery and/or improves 
those that already exist. It is essential to determine the leading compound structure-
activity relationship (SAR), so the newly synthesized derivatives retain its activity (70). 
 
1.1 Development of a new drug 
Drug development can be divided into 3 main phases (Figure 19): (i) drug discovery, 
identification of biochemical, cellular or pathophysiological mechanism, identification and 
validation of a molecular target; (ii) drug development, identification of lead structure, 
followed by design, testing and fine-tuning; (iii) and commercialization (94).  
Nowadays, HTS is becoming more useful to identify hits with significant activity. 
Biological screening has been the main technology used in hit discovery, but biophysical 
or in silico screening is also becoming popular. Hits validation is needed in order to 
eliminate artifacts and determine SAR. Then, these hits will be clustered and prioritized. If 
the hit belongs to a class of compounds, a hit series, it could be the starting point for 
derivative synthesis. Validated hits follow to hit-to-lead optimization, and chosen leads will 
have its PK and toxicity evaluated. In lead optimization step, new lead series derivatives 
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are synthesized, and have their toxicity, PK and pharmacology evaluated. If the project is 
successful, these leads can be tuned and follow to preclinical development (94, 98). It is 
common to centralize early phases of drug discovery until identification of lead series. 
Meanwhile, parallel screens with large compound libraries, aiming at drug targets, are 
done (94). 
The drug discovery process used to last 7 to 12 years, but now it can be completed in 
3 years. This time reduction in mainly due to HTS help in the identification of lead 
compounds from large libraries, which accelerates the process into lead optimization. 
Now huge amounts of derivatives can be generated and characterized (94, 98). 
 
Figure 19. An innovative lead discovery strategy for NTDs (59). 
 
1.2 Screening methods 
The discovery of new drugs for NTDs has been carried by 3 different strategies (82): 
• Label extension of existing treatment indications to NTDs. This approach reduces 
cost and time to market for new drugs. However, many companies do not allow their 
products to be developed for NTDs, because unexpected toxicities could deteriorate the 
drug image. 
• The ‘piggy-back’ strategy is used when a parasite molecular target is being 
evaluated for other indications. SAR from parasite assays is not the same as the original 
indication. So, clinical candidates from will be mainly disease-specific. 
• De novo drug discovery focuses on the identification of new chemical molecules. It 
relies on HTS and medium throughput screening (MTS) in whole-parasite assays against 
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specific proteins and whole parasites. HTS techniques for whole-cell screening have been 
preferred, because of its simpler use. Studies using compound libraries with registered 
drugs have led to great results. Also, chemo-informatics methods plus genomics, in silico 
screening, structural determination of proteins and their co-crystallization with small 
molecules, are being applied in drug discovery. The main disadvantage of this approach 
is the low throughput of the available assays, and the limited investment in development 
of new robust assays. So far, the target-based HTS has yielded few success stories, 
because many compounds active in target-based assays are inactive in whole cells. This 
can be due to the inability of the compound to permeate through cells and because the 
chosen targets are not in fact the real target. So, whole-cell-based HTS is becoming more 
useful and target-based HTS should be seen as complementary. 
HTS has become one of the most used techniques for drug discovery in 
pharmaceutical industry (99). The development of a HTS assay has high maintenance 
and support costs. Besides having possible limited accuracy and low quality of the 
screening, it is highly compensated by the large number of compounds evaluated. 
Increasing the size of screening libraries did not led to new hit classes, and produced a 
high false positive rate (94). Computational filtering of the libraries optimizes the physical 
properties of molecules for drug likeness and rejects the unfavorable ones. Screening 
with compound libraries based on quality, instead of quantity, should increase the quality 
of data obtained from HTS (99). HTS has an automated process for plate preparation, 
liquid handling and detection. It also has data management for tracking, analysis, storage 
and visualization (93). Comparing HTS leads to their corresponding hits, it can be seen 
that leads are more complex, more lipophilic and more flexible than the original hits. HTS 
leads are more drug-like than lead-like. The molecular structure of HTS hits is kept during 
hit-to-lead optimization (94). 
HTS primary screens have a single read-out to facilitate active compounds selection. 
For this, data from multi-parameter assays are reduced into crucial parameters for hit 
selection. Actually, most multi-parameter assays are seen as a single parameter read-out. 
Other parameters are only used to indicate toxicity or to divide sub-populations of cells. 
Secondary HTS screens are smaller and are more flexible. The goal is to understand the 
mechanism of action or toxicity. Selected parameters are scrutinized in a dose-response 
manner. Multi-parameter profiling provides more information about the mechanism of 
action of a compound than a biochemical screen. Compound activities are concentration 
dependent and non-specific toxicity occurs at high concentrations. The compounds must 
be compared at effective concentrations (100). 
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Alternative techniques have been used, but the pipeline always begins with HTS, 
unless a suitable assay cannot be established. Most of the non-HTS based hit discovery 
is fragment-based approaches, followed by virtual screening and natural-product-based 
approaches. The non-HTS hits are weak binders, and HTS-based leads are more 
lipophilic and have higher molecular weight. Fragment hits have low molecular weight and 
complexity, but leads are larger, and have similar physicochemical profiles to other leads. 
Natural products are more complex and more difficult to optimize. HTS achieve this 
optimization by lipophilicity, while fragments and natural products attain by 
complementarity and balanced properties. Increased potency is one of the main goals of 
the hit-to-lead phase, and it is lipophilicity dependent (94). RNA interference (RNAi) is 
also a screening method and it is very useful. A knock-out key gene and its related 
protein lead to impaired parasite function, and it may indicate a potential drug target (97). 
Quantitative HTS (qHTS) increases drug discovery efficiency and provides a 
“chemical genomics” database. Complex biological responses can be read from curve 
shape. This technique bypasses chemical activity identification from post-HTS 
confirmatory assays to automated primary HTS (90). 
High-content screening (HCS) method enables scientists to extract and better 
understand multiparametric data, produced by high-throughput cellular imaging. HCS is a 
valuable tool for biological pathways comprehension, efficacy and compounds safety 
characterization, screening identification and liable evaluation. This allows drugs acting 
on new targets identification with almost no knowledge about its pharmacology. It is a 
“target agnostic-nature” strategy (101). 
 
1.3 Drug discovery strategy at Institut Pasteur Korea (IPK) 
Usually, drug discovery process is developed for one specific drug target, and the 
drug is designed according to it. Instead of, for example, targeting an enzyme, the whole 
parasite cell is targeted. Then, by viability assays, the activity of the drug can be 
measured. The efficient drug is the first to be identified, and only after the target will be 
researched. The target-to-drug approach is not very efficient when compared to drug-to-
target. The lack of promising molecular targets is clear and can be seen in this review. 
Many promising drug candidates are being evaluated as antileishmanials and their 
mechanism of action is not completely known yet. Many of these compounds were 
identified in natural products extracts screenings. It is also known that data obtained from 
compounds screening is less equivocal and in higher volume. 
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At IPK, the screening is made directly into the macrophage-amastigote model. 
Therefore, several steps are bypassed. Only the molecules able to penetrate through the 
macrophage and parasite will be efficient. The others will be ruled out, and the discovery 
process will become faster and simpler. Specific software was developed for these 
screenings and it enables automation of the process, turning it into a faster and more 
accurate method. Software provides better predictivity. HCS images with high quality can 
provide important information (101). 
Large library of small compounds can be screened by HTS. These compounds are 
the molecules active backbones. Cellular imaging is used for the identification and 
provides accurate large-scale assays. After the identification of the hit compounds, SAR 
studies are made, derivatives are synthesized and the active scaffold is identified. After 
hit-to-lead optimization, the lead optimization will provide a molecule that will be submitted 
to in vivo PK assays. This molecule will have, approximately, a 100 times higher potency. 
The lead optimization process can be more difficult because of the ignorance of its 
structure. 
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2. Cell-Based Assays 
A cell-based assay may be sufficient for preclinical development, if the phenotype of 
interest is well defined. Quantitative phenotypic profiles can help to predict SAR. The cell-
based SAR may not be as precise as biochemical assays SAR, but it reflects the 
therapeutic value. Knowing a biological target can accelerate the hit-to-lead phase but is 
not a limiting factor (100). 
Cell-based assays are increasingly being used in drug discovery because they reflect 
more accurately the complexity of the entire living organism. Cell-based screens are 
called black-box screens, and have higher hit rates than biochemical screens. It is 
mandatory to filter these hits for further development and evaluate their efficacy and 
toxicity. The cellular phenotype is complex and multiplexed measurements must be done. 
Filtering HTS hits requires high throughput, while studies to determine the mechanism of 
action and toxicity requires a greater range of read-outs. Multi-parameter profiling 
technologies and multi-parameter phenotypic profiling include transcriptional, proteomic 
and cell imaging measurements. Transcription profiling using a complementary DNA 
(cDNA) micro-array is a standard technique. Its application in MTS has limitations, such 
as high cost and poor results comparability. Quantitative polymerase chain reaction 
(qPCR), MS and bead-based immunofluorescence technology are higher throughput 
gene signature-based methods. So, they are better for large-scale profiling, but very 
expensive. Data analysis in phenotypic profiling goals is the stratification of hits, 
identification of mechanism of action and characterization of toxic mechanisms. Target or 
mechanism of action profiling can be made by comparing the phenotypic profiles of new 
compounds with reference bioactive compounds (100). 
Fluorescence-activated cell sorting (FACS) and microscopy generate descriptors for 
every cell for each treatment. FACS and microscopy read-out phenotypic profiles of 
compounds in single cells and generate large amounts of data. So, active compounds in 
a specific sub-population of cells can be determined. The compound profile is the 
combination of response parameters of many sub-populations (100). 
Proteins and their modifications are cellular activity biomarkers. So, proteomics is an 
important tool in target and biomarker discovery. Enzyme-linked immunosorbent assays 
(ELISAs) or immunoblotting-based protein assays are being used to monitor protein 
changes in HTS. Protein MS enables better fractionation methods and instrument action. 
Protein-compound interactions can also be monitored by MS. Quantitative methods can 
determine differential protein binding. The enhancement of multidimensional liquid 
chromatography (LC) and adaptation of a target-based approach could improve the 
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sensitivity and reproducibility of proteomic profiling. Proteomics is limited by low 
throughput of protein detection in complex mixtures by MS and the equipment’s high cost 
(100). 
Multi-parameter cell-based assays are screening and profiling tools for target, 
mechanism of action and toxicity identification. Screening must identify compounds with a 
desirable profile. These assays should have reasonable throughput, simple analysis 
matrices and robust criteria to discard toxicity (100). Comparative modeling may be useful 
to study new drug targets, identify binding sites for small molecules, suggest drug leads 
and optimize these. There is software that predicts the interaction between large-scale 
protein structures, known drugs and their ligand binding sites. These can increase the 
pipeline efficiency in target identification and validation, lead discovery, optimization and 
clinical trials. This approach can also help to determine the mechanism of action of 
already known drugs (102). 
Another alternative is virtual screening (99). It is based on computational screening of 
large libraries which target of known structure, and their binding affinity is evaluated. If the 
molecular structure of a receptor is known, its function can be understood and predicted. 
New ligands have been discovered using this technology. The structures of known 
ligands in complex with their receptors are predicted. These docking screens rank the 
molecules by affinity. Virtual screening avoids syntheses and limits the search to 
compounds with biological relevance or drug likeness. Virtual screening follows the same 
guidelines as HTS. It has limited accuracy, but provides screening on a large scale. It 
produces many false-positive hits. Virtual screening is more accessible than HTS (103). 
 
2.1 Biological Assays for Leishmania 
The biological assays required to discover new drugs for leishmaniasis are in vitro 
assays with promastigotes and amastigotes of different species in dividing macrophages, 
which can indicate drugs’ activity at achievable concentrations in serum/tissues and in 
vivo assays to study the molecule’s PK (70, 78). A huge limitation of the amastigote-
macrophage in vitro model is the non existence of automation and the need of 
microscopical evaluation (78). 
In drug screening, promastigotes are not as useful as amastigotes. Amastigotes 
provide information about drugs’ ability to permeate through biological membranes. The 
role played by the host cell on drug-mediated toxicity is important, limiting availability or 
favoring toxicity. The toxicity data against the host cell must be collected before testing 
against the amastigote (104). 
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Amastigotes derived from CL and VL strains are able to multiply in vitro in human 
monocyte-derived macrophages, and this model is closer to in vivo situation (27). THP-1 
cells are a representative macrophage cell line useful as investigative model, which 
derive from a human with acute monocytic leukemia. These cells are phagocytes that 
produce lysosomes and esterases. 4α-phorbol 12-myristate 13-acetate (PMA) is used for 
THP-1 cell differentiation (105, 106). After differentiation, they become adherent and very 
similar to natural macrophages (105). THP-1 cells present same morphology, surface 
membrane receptors, oncogene expression and cytokines production as natural 
macrophages (107). Nevertheless, they have very different genetic expression from 
natural macrophages (105). 
THP-1 cells undergo monocytic pathway changes with phorbol esters (PEs) 
incubation. PEs activate PKC, because they mimic diacylglycerol. 1,25-dihydroxyvitamin 
D3 (VD3) can also lead to this differentiation. Comparing both differentiation methods, 
PMA provides macrophage-like morphology, proliferation loss, CD11b expression, 
phagocytosis properties and prostaglandin E2 (PGE2)/TNF-α increased release. On the 
other hand, VD3 leads to a monocytic-like morphology, no adherence, and it does not 
interfere with proliferation or PGE2/TNF-α production (108). 
Intracellular amastigotes (InAs) (Figure 20) adhere to vacuoles and replicate slowly, 
so these do not rupture. Axenic amastigotes (AxA) do not show this limitation. InAs 
promote macrophage’s functional and structural integrity maintenance. However, this 
varies with the infection stage. Inside PVs, amastigotes may degenerate and undergo 
cytolysis or apoptosis. Infection sites present high levels of InAs and few free extracellular 
amastigotes. Amastigotes replication is limited, but crucial for infection maintenance 
(109). 
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Figure 20. InA inside PV of J774G8 macrophages after long-term infection with L. amazonensis. (A) 
Amastigotes adhered to vacuolar membranes. (B, C) Amastigotes in smaller vacuoles in J774 cells 
undergoing mitosis. (D) Intact, but degenerating macrophage infected with more than 100 amastigotes. 
Arrows point to apparently degenerating amastigotes. Bar = 10 µm (109). 
Amastigote-macrophage model is considered the “gold standard” for drug screening. 
Amastigotes can be isolated from short-term in vitro cultures in murine peritoneal 
macrophages (110), human macrophage cell lines (111) or infected tissues (112). 
Amastigotes isolated from lesions are often contaminated, exist in a limited number and 
present adsorbed host components (111). 
InAs are the best approach for drug screening and their production in THP-1 cells is 
the most reliable Leishmania infection model (113). InAs are less time consuming, show 
biological parameters more similar to amastigotes isolated from lesions and do not 
present relevant contaminants (111). 
AxAs are an alternative and more practical way for infection, which can be used in 
drug screening and vaccines research. However, long-term culture may promote 
promastigote-like features (113). AxAs need a culture medium with lower pH, higher 
temperature and a specific composition. Many biochemical profiles have shown similar 
morphological and biochemical features to parasites isolated directly from lesions. AxAs 
have comparable morphology, biochemistry, infectivity, cyclic transformation and 
immunochemical molecular characterization. Nevertheless, it must be reminded that AxAs 
are not in a natural environment, which fully mimics intracellular conditions. This is a huge 
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limitation comparing to InA. Also, promastigotes stage can be important for axenic 
differentiation. For instance, L. amazonensis and L. mexicana require metacyclic 
promastigotes in order to transform into AxA (111). On the other hand, L. amazonensis 
(35), L. donovani, L. mexicana (114), L. peruviana (106, 111) and L. pifanoi do not have 
this requirement and AxAs are relatively easy to obtain. Though, L. major does not 
provide good AxA production (111). 
Promastigotes are easier to cultivate in vitro than amastigotes (111, 113), but they 
should not be used for drug screening purposes. They are not good biological models to 
screen immunomodulatory compounds. For this purpose, InA are preferred, because they 
cohabitate with immune system cells, such as macrophages. This way, a natural infection 
can be mimicked and immune response factors can interact with the screened drugs, 
providing more reliable data (115). 
For drug screening optimal benefits, it is very important to characterize the 
promastigote population present in a given culture. In order to achieve higher infection 
rates, metacyclic promastigotes should be used. Standardization is needed, to diminish 
infectivity rate variation. There are many methods described in the literature for 
metacyclic promastigotes purification. However, none of them seems to be completely 
reliable. Metacyclic promastigotes purification by lectins, such as PNA, or monoclonal 
antibodies is based on oligosaccharides polymorphisms present on the parasites surface 
(116). Assuming that metacyclogenesis is triggered by lower pH and higher temperature, 
Luz et al. (2009) studied how preconditioning promastigote could influence infectivity 
ratio. This group study pH lowering, in order to check intracellular infection and its 
reliability. They were able to prove higher amount of metacyclic promastigotes in culture 
after induction, than for the spontaneous culture (117). 
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3. Cellular Imaging 
Cellular imaging techniques are very interesting for target discovery, lead 
optimization, in vitro toxicology and compound profiling. It provides the visualization of a 
cell population, single cell or sub-cellular structures, with image-analysis tools. Currently, 
it is used for secondary screening and lead optimization. Generally, a 96- or 384-well 
plate is used for low-resolution application. The images are collected from each well at 
different magnifications and processed by integrated software, which analyzes each 
image, recognizes appropriate cell patterns and measures relevant features. The 
parameters must be robust, sensitive and reflect the biology. Although these assays are 
more robust, they are still complex and expensive (95). 
The detection systems can be microscopes, fluorescence macroconfocal detectors or 
fluorometric imaging plate readers with charge-coupled device (CCD) cameras. These 
systems create a 2D pixel array of information from a biological sample. The imaging 
system should allow high-resolution analysis of single cells, high throughput, kinetic 
studies on live cells and efficient data storage and compression systems in user-friendly 
image-analysis programs. Modern imaging platforms are fast and able to test many 
conditions simultaneously (95). 
Cellular imaging has been used in the analysis of fixed tissue or cell samples. Visible-
light microscopy provides non-invasive 3D imaging, and it is used in laboratories to 
investigate targets in cellular phenotypes. Fluorescence microscopy is very important and 
confocal microscopy is very used because it is simple to use and allows the imaging of 
cells in optical sections at high resolution. Laser-scanning microscopes are similar to 
confocals, but with faster sectioning. Fluorescence resonance energy transfer (FRET) 
technology detects the transfer of energy from donor to fluorophore acceptor, providing 
better spatial resolution. This transfer can be captured by confocal or multiphoton 
microscopy. Temporal resolution of protein-protein interactions can be done by 
fluorescence lifetime imaging (FLIM). FLIM monitors detect changes in the fluorescence 
lifetime and analyze dynamic changes. FLIM and FRET can show evidence for physical 
interactions between proteins (95). 
In flow cytometry, suspended cells are individually passed by a focused light source, 
and these are labeled with fluorescent antibodies. Flow cytometry can be used to isolate 
cells from a mixed population, identifying sub-populations. Flow cytometers are being 
increasingly used in biomarkers assays, to identify markers able to measure drug efficacy 
in preclinical and clinical stages. Automated microscopy and high-throughput flow 
cytometry make quantitative measurements for single-cell using multiple fluorescent 
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channels. Flow cytometry provides data on more cells because of its speed, is highly 
sensitive and easier to multiplex because of its simpler optical set-up. On the other hand, 
microscopy-based read-outs provide more information on each cell because it has 
superior spatial resolution. These differences are fading, because flow cytometers with 
imaging capability are being developed and microscopy read-outs have become faster. 
Still, it is easier to analyze non-adherent cells by flow cytometry and adherent cells by 
microscopy. Microscopy-based assays are better for HTS than cytometry, because fixed 
and stained cells can be stored. 
Fluorescence microscopy has great potential to become a high-throughput and highly 
multiplexed profiling tool, because only a small number of cells are needed. HCS can 
measure many cell parameters, generating huge amounts of data. Nevertheless, live cell 
microscopy remains an interesting area in which HTS and image analysis are under 
development. Automated microscopy enables automated cell image acquisition and 
analysis, with high throughput and spatial resolution. 
The challenges in phenotypic profiling are: combining data generated by HTS; 
implementing profiling on cell types; using data-mining methods and to get information; 
and developing technologies to acquire and handle single-cell and time-dependent 
information (100). Cytometric bead arrays and flow cytometry or fluorescence macro-
confocal imaging allow seeing how disease phenotypes can be modulated. At low 
resolution, it is possible to quantify phenotypic changes, and at high-resolution mode, 
sub-cellular changes can be quantified (95). 
 
3.1 Confocal microscopy 
Several types of confocal microscopes are available. The most commonly used for 
fluorescence microscopy are laser-scanning fluorescence microscopy (LSM). These 
microscopes use lasers as light sources and collect images by scanning the laser beam. 
Lasers provide intense illumination within a narrow range of wavelengths (118). LSM can 
be classified as two photons LSM (TPLSM) or confocal LSM (CLSM). TPLSM has a 
better spatial resolution, and provides 3D reconstruction based on image stacking. This 
technology allows imaging in UV spectrum and deeper sample penetration (119). Two-
photon excitation occurs when a fluorophore simultaneously absorbs 2 photons, each 
having half the energy needed to raise the fluorophore to the excited state. The light 
intensities required for simultaneous absorption occur at focal point, so only fluorophores 
at focal point are excited. It allows optical sectioning without spatial filter in front of the 
detector. The wavelengths needed to excite standard visible light fluorophores by two-
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photon absorption are longer and penetrate tissue better than the wavelengths used for 
one-photon excitation, making it possible to look deeper into a specimen (118). 
CLSM detects fluorescence point-by-point or line-by-line. Point scanning leads to 
higher contrast and resolution, but low scan speed. Spinning disk confocal microscope 
has a multibeam excitation or whole field imaging detection system, with higher speed, 
and less damaging for biosamples. There is a limited penetration depth, and there is a 
significant difference between axial and lateral resolution (120). LSM enables 
visualization deep in live and fixed cells and tissues, is 3D with high-resolution and is non-
destructive (119). One of the major applications of CLSM is multiple label imaging. 
Confocal microscopy can merge a non-confocal transmitted light image with fluorescence 
images. Fluorescent proteins can be used as reporters of different spectral properties, 
providing multicolor labeling. Brainbow technique allows the use of 90 labels, being all 
these detected in a single sample with a standard laser scanning confocal microscope 
equipped with a spectral detector (121). 
Confocal microscopes (Figure 21) are light microscopes that use lasers and very 
small apertures to produce images of thin layers of samples. It provides higher resolution 
and optical sectioning without out of focus light degrading the image. After, these layers 
can be reconstructed and a 3D image can be recreated. Confocal microscopy is often 
used with fluorescent techniques. Fluorescence can highlight and allow visualization of 
naturally or derivatized fluorescence. 
Confocal microscopy can give qualitative information about topography, morphology 
and composition of the sample, in µm. Quantitative information is possible with counting 
methods. Confocal microscopy has the ability to control depth of field and ability to collect 
serial optical sections from thick specimens (119). Light is collected from thin optical 
sections, representing single focal planes. Focal plane structures are better defined (118). 
Thin section images can be produced, avoiding physical sectioning or compression. 
Confocal microscopy is very popular due to its high-quality images (119). 
The light source is a laser, which uses the objective lens in the discriminator to focus it 
onto different planes on the sample. The sample is placed on a slide and on a stage. The 
objective lens is the discriminator, and it forms a real intermediate image that is detected 
by the photomultiplier tube (PMT). The PMT gets the image and transfers it to a computer 
for magnification. Then, the images are displayed digitally on a monitor and can be 
manipulated (119).  
Fluorescent molecules excited by incident light emit fluorescence in all directions. The 
fluorescence collected by the objective comes to focus in image plane, which conjugates 
with the focal plane. A pinhole aperture in the image plane allows fluorescence from the 
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illuminated spot in the specimen to pass to the detector, but blocks out of focus light. The 
separation of in focus signal from out of focus background is done by pinhole aperture 
(118). 
 
Figure 21. Confocal microscope schematic figure (118, 119). 
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 V – Materials and Methods 
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1. Cells Culturing 
Parasite’s culture 
Leishmania spp. promastigotes were cultivated in axenic M199 culture medium 
(Sigma-Aldrich), supplemented with 100 U/mL penicillin and 100 µg/mL streptomycin 
(Gibco), 4.6 mM NaHCO3 (Sigma), 40 mM HEPES (Sigma; pH 7.5), 0.1 mM adenine 
(Sigma), 4 nM biotin (Sigma) and 10% heat-inactivated fetal bovine serum (FBS) 
(Gibco) for L. major (MHOM/IL/81/FRIEDLIN), L. donovani (MHOM/ET/67/HU3) and L. 
amazonensis (MHOM/BR/73/M2269), and 20% FBS for L. braziliensis (MHOM/BR/2903). 
L. major, L. amazonensis and L. braziliensis cultures were started at 5x105 
parasites/mL and L. donovani cultures at 106 parasites/mL. Promastigotes were counted 
on C-Chip hemocytometers (InCyto) after being fixed with a 4% paraformaldehyde (PFA) 
(Sigma-Aldrich) solution. 
Maintenance cultures were grown in T75 flasks (Nunc) at 28 °C with closed caps in 
a final volume of 10 mL. These were sub cultured every 3 to 4 days. Cultures used for 
macrophage’s infection were grown in T175 flasks (BD Falcon) at 28 °C with closed caps 
in a final volume of 100 mL. For infection assay number 2 and 3, 24 hours before each 
infection, 5 mL of L. donovani culture were incubated at 37 °C and the other Leishmania 
species at 34 °C. 
Macrophage’s culture 
THP-1 cells were cultivated in suspension at a density of 5x105 cells/mL and Raw 
264.7 cells at 8x105 cells/flask in RPMI 1640 medium (WelGene) supplemented with 100 
U/mL penicillin, 100 µg/mL streptomycin and 10% heat-inactivated FBS. Both cell lines 
were incubated at 37 °C with 5% CO2. Subcultures were made every 3 to 4 days. THP-1 
cells differentiation into macrophages was induced by PMA addition (Sigma-Aldrich), 
and then incubated for 48 hours, in a final solution of 50 ng/mL. 
 65 
2. Infection Assays 
Before infection, all cells were counted, centrifuged (promastigotes at 2500 rpm and 
macrophages at 1500 rpm for 5’) and resuspended in RPMI 1640 medium. Then, 10 µL of 
promastigotes suspension were added to 40 µL of THP-1 or Raw 264.7 cells (50 
parasites for 1 macrophage host cell) in Greigner 384-wells Plate (Bio-One). 
Infection with L. donovani, L. major, L. amazonensis and L. braziliensis was made 
both for THP-1 and Raw 264.7 cells. One infection plate was done for each day of 
parasite’s culture, from the 3rd day until the 10th. Then, the infection was kept for 6 days 
and the plates were incubated at 34 or 37 °C, in a 5% CO2 atmosphere. 
24 hours after, infection was washed with a phosphate buffered saline (PBS) 1x 
solution  (Welgene). First infection day columns were fixed with 2% PFA solution and the 
remaining infection day’s columns were added 50 µL of RPMI 1640 medium. After, every 
24 hours, the corresponding infection day column was washed and fixed. 
When all columns were fixed, the plates were again washed with PBS 1x solution and 
stained with 5 µM Draq5 (Biostatus), in 4% PFA solution. Infection plates were then read 
in Evotec Technologies Opera (Perkin Elmer) and in ImageXpress Ultra (Molecular 
Devices). The images acquired were analyzed. Parasite infection ratio and number of 
amastigotes per infected macrophage were determined. 
In total, 4 whole infection assays were done. Below, there is an overview of what was 
done for each experiment set. 
Infection assay number 1 
All parasites were incubated at 28 °C and infected cells at 37 °C. Infection plates were 
read in Evotec Technologies Opera™, with 20x magnification. The plate format used is 
represented on Figure 22 
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Figure 22. Plate format used for infection assay number 1, incubation made at 37 °C. 
Infection assays number 2 and 3 
For each infection day, promastigotes from 2 different incubation temperatures were 
used, in order to mimic vector and host temperature. Vector incubation temperature was 
28 °C for all Leishmania species, but host temperature was 37 °C for L. donovani and 34 
°C for the other remaining species. The plates were incubated with 5% CO2 at 37 °C, for 
L. donovani, and at 34 °C for the other Leishmania species. 
Parasites were incubated at 37 °C 24 hours prior to infection. Cells infected by L. 
amazonensis, L. braziliensis and L. major (CL and MCL strains) were incubated at 34 °C, 
and cells infected by L. donovani (VL strain) at 37 °C. After, all infection plates were read 
in Evotec Technologies Opera™, with 20x magnification and, only for infection number 3, 
also with 40x. The plate formats used are represented below. On Figure 23, there is the 
plate format representation used for incubation at 34 °C and on Figure 24, the one used 
at 37 °C. 
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Figure 23. Plate format used for infection assays number 2 and 3, incubation made at 34 °C. 
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Figure 24. Plate format used for infection assays number 2 and 3, incubation made at 37 °C. 
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Infection assay number 4 
All parasites were incubated at 28 °C and infected cells at 37 °C. Infection plates were 
read in Evotec Technologies Opera™, with 40x magnification, and in ImageXpress Ultra, 
with 20x magnification. The plate format used is represented on Figure 25.  
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Figure 25. Plate format used for infection assay number 4, incubation made at 37 °C. 
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3. Replication Assays 
Infection was carried on 24-wells plates (Corning) using coverslips and done as the 
infection assay described for 384-wells plate. Wells supernatant was rejected 24 hours 
post-infection and coverslips were incubated 12 hours with 1 mM bromodeoxyuridine 
(BrdU; Sigma) and deoxycytosine (dC) (GE Bioscience) solutions, in a final volume of 
200 µL. 
Then, coverslips were washed 3 times with PBS 1x solution, incubated with absolute 
methanol (4 °C, 10 min; Merck), HCl 1.5 M (4 °C, 15 min; Fluka, Sigma) and Triton X-
100 0.1% (4 °C, 10 min; Sigma-Aldrich). All solutions were prepared in sterile PBS 1x 
solution. 
In order to show cellular replication, the fixed infection was probed with primary 
antibody anti-Br (1:400 dilution in 4% bovine serum albumin (BSA); Molecular Probe, 
Gibco) and secondary antibody anti-IgG Alexa Fluor 488 (1:400 dilution in 4% BSA, 4 
°C, 45 min; Molecular Probe). Then, DNA was stained with DAPI, (1:2000 dilution in 4% 
BSA, 4 °C, 45 min; Sigma). Between steps, coverslips were washed twice with PBS 1x 
solution. 
In the end, probed coverslips were placed in glass slides with 2 µL of Vectashield 
(VectorLabs). Analysis was carried in Nikon Eclipse 90i epifluorescence microscope. 
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4. Image and Data Analysis 
Our aim in developing an image-processing pipeline is to detect cell infection ratio 
under the conditions described in previous sections of this chapter. In doing so, we must 
detect intensity patterns of Leishmania parasites within the cytoplasm of cells in images. 
This requires 2 distinct detection methods for cytoplasm regions and for a number of 
parasites within the detected regions. For the detection of cytoplasm regions, the 
following preprocessing steps are applied to the images (Figure 26): 
• Background removal; 
• Resizing; 
• Gaussian blurring and local intensity maxima. 
The purpose of the first preprocessing step is twofold. A successful removal of the 
background greatly improves the processing time. Secondly, it reduces the number of 
false positive detections of cytoplasm. In order to carry out the first preprocessing step, 
we must first obtain a range of background intensity values from the collection of acquired 
images. Also, since the images were acquired under the same conditions, we may safely 
assume that there exists such range of values we may apply across the whole collection 
of images. For our screening purposes, 3 scientists were assigned to 3 different subsets 
of images for random sampling of background intensities. All 3 reported that the 
background intensities range, from which we applied a threshold for background removal 
step. The second preprocessing step is also to reduce the processing time of the 
detection method. Originally 2000 by 2000 images are reduced to 1000 by 1000 by 
bilinear interpolations of pixels values. The final step of the preprocessing is to detect 
intensity local maxima with a given window size where we locate the positions of nuclei. 
The assumption is that there exists only one nucleus per cell such that the locations of the 
local maxima coincide with the center of the nuclei. These local maxima positions are 
used as a discrete set of points for Voronoi tessellation for detection of cytoplasm areas. 
By overlapping the detected areas of the cytoplasm with the parasite detection, which we 
will explain in the following paragraph, we may compute infection ratio. 
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Figure 26. A diagram of the pipeline for image processing unit of leishmaniasis infection rate detection 
algorithm. 
Parasite detection method shares the first preprocessing step as the cell detection 
algorithm. It also initiates detection by locating local maxima. However, the window size of 
the local maxima detection is fit to model parasite sizes, rather than the sizes of nuclei. As 
the 3D plot of intensity values of cell body and parasite in Figure 27 shows, the number of 
connected pixels that compose parasites is much smaller than that of the nuclei. 
Therefore, we may obtain salient points, which may potentially be the center of parasites 
 72 
by detecting the local maxima. Once the salient points are obtained, the method builds a 
parasite model from a randomly selected set of point locations. The procedure of building 
of the model broadly involves the following sequential steps: 
• A manual user selection of random point locations for training set data; 
• A bidirectional decomposition of neighboring pixels at the selected points; 
• Computations of a range of means and standard deviations by Levenberg-
Marquardt algorithm. 
 
Figure 27. Intensity patterns of Leishmania parasites compared to the patterns of nuclei. 
In essence, the method determines the Gaussian distribution (Figure 28) fitting 
shapes of parasites through solving least squares curve fitting problems with the user 
supplied local data. By selecting a wide range of different shapes of parasite, the method 
is ensured to obtain a reliable representation of parasite model across the collection of 
acquired images. The method then measures how well the locations of the local maxima 
represent the model acquired by computing the distance between the decomposed 
distributions at the locations and the model we built from the train set data. 
The 2 different detection methods described above are diagramed in Figure 26. The 2 
processes run in parallel then overlap at the last stage of the overall process to compute 
the infection ratios by counting the detected parasites inside each detected cell region. 
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Figure 28. A Gaussian modeling of Leishmania parasites pattern on HTS acquired images. 
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 VI – Results and Discussion 
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1. Infection Images 
The results presented on this dissertation derive from a phenotypic interpretation of 
infection development in 4 Leishmania species, in 2 macrophage cell lines. Some images 
acquired during infection assays are shown as examples in Figure 29 and Figure 30. 
These figures respectively illustrate THP-1 and Raw 264.7 cells infected with Leishmania 
parasites throughout 6 infection days. 
 
Figure 29. THP-1 cells infection with promastigotes from 6th day of culture. 
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Figure 30. Raw 264.7 cells infection with promastigotes from 6th day of culture. 
From these pictures overview, it could be hypothesized that THP-1 cells showed 
higher infection ratios, and InA were easier to detect. THP-1 cells stop dividing after PMA 
differentiation. So, there was always a constant cells’ confluence on the well’s bottom, 
proving better and more consistent results. On the other hand, Raw 264.7 cells kept 
replicating and on the last days of infection, cellular debris could be seen. The cell 
monolayer was not uniformly distributed and led to more variable results. 
In order to confirm visualized impressions and hypothesis, software was especially 
developed to allow automated and unbiased image mining analysis of the data. 
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2. Image Mining 
Infection assays’ images were acquired by confocal microscopy. So, it must be taken 
in consideration that only one single focal cell plane was acquired. This fact implicates 
that not all parasites on the well bottom were detected. 
Analyses were performed in an automated fashion by an algorithm developed for 
image analysis. Automated analysis from software detection was susceptible to 
misinterpretation of few images, such as identification of false parasites (artifact or 
chromatin condensation) and not identification of true parasites. Software was optimized 
in order to reduce as much as possible these false positives and false negatives. It was 
possible to adjust and control some parameters for data analysis, optimizing software 
accuracy in the phenotypic interpretation (Figure 31). 
 
Figure 31. Software tuning interface. It enables control of background removal, cell segmentation and parasite 
detection parameters. After careful tune, these parameters can be saved and loaded later for another 
experiment analysis. 
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Figure 32 illustrates a confocal microscope image and how the software developed at 
IPK analyzes it. This image results from all the tuning made by interacting with the 
software, and it could be improved by constant testing at anytime. 
A B
C D
 
Figure 32. Software analysis of confocal microscope images. The original image (A) is tested for cell 
segmentation (B) and parasite detection (C). Then, software analysis image D. 
The original images were subjected to many different analysis parameters, in order to 
mine as much information as possible. As a first step, sampling of the image was done, in 
order to determine the expected amastigote’s intensity inside host cells. After background 
removal, the cells were identified and segmented (Figure 32 – B). Then, parasites were 
detected, as shown in red dots from Figure 32 – C. Figure 32 – D illustrates the 
interpretation of software analysis, after algorithm implementation over the raw image. 
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Figure 33 shows non-infected macrophages. The software detects some few false 
parasites. Results can be normalized after the knowledge of (false) infection ratio of non-
infected macrophages, the negative control. 
A B
 
Figure 33. Negative control original (A) and processed image (B). 
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3. Infection Optimization 
3.1 Promastigote fitness optimization 
This project’s first aim was to establish the best day of promastigote in vitro culture 
that led to the highest macrophage (human and murine) infection ratio. In vivo infection 
and disease establishment is very complex, involve several factors from host immune 
system, and is not comparable to the results obtained in any in vitro work. Our purpose 
was to compare different species of the parasite and host cells, in order to get optimal 
infection conditions for each species. So, an optimal in vitro infection system could be 
established and used as a study disease model or as an infection model applied to drug 
screening. 
To perform the analysis, we assumed that after the extracellular parasites were 
washed from the wells 24 hours post-infection, there would not be an increase in the 
infection ratio as there would be no more extracellular promastigotes to infect new host 
cells. The 6th post-infection day was then used as a common factor in all comparisons 
ahead, for the 4 Leishmania species both in THP-1 (Figure 34) and Raw 264.7 (Figure 
35) cells. 
 
Figure 34. THP-1 cells infection ratio overview during post-infection (6 days), with promastigotes from the 5th 
day of culture. 
 81 
 
Figure 35. Raw 264.7 cells infection ratio overview during post-infection (6 days), with promastigotes from the 
5th day of culture. 
As was told on Chapter II, one key factor for infection establishment is the 
differentiation of Leishmania promastigotes into metacyclic state, enabling proper 
adaptation to the macrophage phagocytic vacuole (32). After recent findings, it is also 
known that a successful infection establishment depends on the ratio of apoptotic 
promastigotes versus the metacyclic ones (34). In this sense, to estimate the best time 
from the in vitro promastigote culture, we promoted infection of macrophages from 
different days of promastigote culture. In order to understand if the best promastigote 
culture condition for infection depends also on the macrophage properties, we tested 
infection using 2 different macrophage cell lines: differentiated THP-1, which is a human 
macrophage from an acute monocytic leukemia, and Raw 264.7 cells, which is a mouse 
leukemia macrophage. 
We also tested if in vitro cultures preconditioning improved promastigotes infection 
ability, as mentioned, for example, in Luz et. al (2009). For that purpose, we did infection 
assays with promastigotes incubated at 28 °C, which is the usual in vitro culture 
incubation temperature, and at 34 °C or 37 °C, only 24 hours prior to infection. The 28 °C 
incubation temperature mimics the insect vector temperature. Therefore, it has been 
hypothesized that increasing this temperature to values obtained in the human host (34 
°C for cutaneous strains and 37 °C for visceral strains), infection ratio could be enhanced. 
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The first measured parameters were the ratio of infected macrophages in the period of 
24 hours exposition to the parasites (infection ratio), and the average number of parasites 
phagocytized per macrophage during this time. These parameters are in fact more related 
to the ability of the macrophage to phagocyte parasites, once the infection can be 
considered passive from the parasite point of view. For this reason, we evaluated 
parameters more associated to parasite’s fitness. The extracellular parasites (non 
phagocytized parasites) were washed from the wells 24 hours after the infection moment, 
to avoid late infection. We measured again the infection ratio and the average number of 
parasites per infected macrophage 24 hours after the first measurement (48 hours after 
the infection moment), elucidating how many of the phagocytized parasites could survive 
inside the macrophage, and be able to establish an infection (Table 6). 
Table 6. 3rd day of in vitro culture promastigotes infection in THP-1 cells. 
  
Infection Ratio (%) Average Number of Parasites per Cell 
 Time after infection 
  24 h 48 h 24 h 48 h 
L. donovani 56 55 2.8 2.6 
L. major 40 30 2 1.6 
L. amazonensis 43 32 2.1 1.7 
L. braziliensis 33 28 1.8 1.4 
L. major, L. amazonensis and L. braziliensis promastigotes from the 3rd day of in vitro 
culture demonstrated not to establish infection in efficient way as the infection ratio 
decreased 5% to 10% from 24 to 48 hours post-infection. The average number of 
parasites per cell also decreased in the same time period. Differently from other species, 
L. donovani promastigotes established stable infection, keeping same infection ratio and 
average number of parasites per infected cell from 24 to 48 hours post-infection. 
The infection ratio from 48 hours post-infection can be considered a good 
measurement for stable infection after washing extracellular parasites 24 hours post-
infection, as the phagocytized parasites unable to establish the infection would have been 
eliminated by the macrophage. This elimination of the non-adapted parasites explains the 
decrease in the infection ratio from 24 to 48 hours post-infection and the decrease in the 
number of parasite per infected cell. For all the 4 Leishmania species tested in this 
experiment, the promastigotes from days 5 and 6 (Figure 36 and Figure 37) were the 
most efficient to establish macrophage infection.  
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Figure 36. Infection ratio from promastigote in vitro culture from day 3 to day 9, 48 hours after the infection of 
THP-1 cells. 
 
Figure 37. Infection ratio from promastigote in vitro culture from day 3 to day 9, 48 hours after the infection of 
Raw 264.7 cells. 
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L. donovani was the specie with the highest infection ratio and the specie that 
demonstrated more stability and resistance to macrophage elimination from 24 to 48 
hours post-infection. All the other 3 species (L. major, L. amazonensis and L. braziliensis) 
showed a decrease in the infection ratio from 24 to 48 hours post-infection, indicating that 
macrophages were able to eliminate part of the phagocytized parasites. This fact 
suggests that the parasites were not in optimal conditions for infection. The results were 
consistent both in THP-1 and Raw 264.7 cells, corroborating the hypothesis that the best 
parasite condition for infection establishment does not depend on the host cell. The ratio 
of parasites used in infection was 50 parasites per cell, both for THP-1 and Raw 264.7 
cells. Because this ratio was only optimized for L. donovani infection, maybe, if a different 
ratio was tested, different results could be observed. 
The graphs below (Figure 38) show the different infection ratios obtained with 
promastigote’s incubated at 28 °C and at 34 °C (L. major, L. amazonensis and L. 
braziliensis) or at 37 °C (L. donovani). These temperatures were chosen accordingly to 
insect vector and mammal host temperatures. 
 
Figure 38. Infection ratio comparison between different incubation temperatures, in THP-1 cells. 
As we can see on the graphs, the highest infection peaks for all species occur 
between the 5th to the 7th day of promastigote’s cultures. We must state that obtaining 
precisely only one day of promastigote’s age with the highest infection is imprecise, 
because the culture growth curve is estimated and can be affected by many factors. 
Nevertheless, results were reproducible throughout all experiments. 
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Comparing promastigotes’ culture incubation temperatures, it did not seem to exist a 
correlation between incubation temperature and consequent infection ratio. The highest 
infection ratio peaks for L. major and L. braziliensis occur for promastigotes incubated at 
34 °C. Interestingly, apart from the highest infection day, the other days tended to show 
higher infection ratios for promastigotes incubated at the insect vector host temperature, 
28 °C. For L. amazonensis, the infection ratio was always higher for 28 °C incubated 
parasites, but there was a clear parallelism with infection obtained with 34 °C 
promastigotes. L. donovani showed similar results for both temperatures, but had better 
infection ratios for cultures incubated at 28 °C. 
Figure 39 shows the same comparison above, but for Raw 264.7 cells. L. donovani 
results are not very clear, but it seems that promastigotes incubated at 28 °C led 
generally to higher infection ratios. L. amazonensis also showed the same trend as L. 
donovani, better infection ratio for promastigotes incubated at 28 °C. Once again, L. major 
and L. braziliensis showed higher infection ratios with parasites incubated at 34 °C. Such 
as for THP-1 cells, infection ratios had the same range of values and similar trends for 
both incubation temperatures. 
 
Figure 39. Infection ratio comparison between different incubation temperatures, in Raw 264.7 cells. 
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3.2 Optimal infection day 
Another aim of this project was to shed some light into, still unclear, infection 
development during the parasite cycle inside the host cell. Figure 40 and Figure 41 
correlate the number of parasites per infected cell with post-infection day. 
In order to choose the optimal post-infection day for each cell line, we must consider 
some key points. Because THP-1 cells do not multiply after differentiation, and because 
infection is washed 24 hours post-infection, we considered infection to be constant 
throughout all post-infection. Only the number of parasites inside infected cells 
(amastigotes) should vary. The same does not occur with Raw 264.7 cells. These cells 
can multiply during the infection assay, and, therefore, infection ratio can vary during the 
post-infection period. 
According to Figure 40, for THP-1 cells, any day during post-infection provided, 
theoretically, the same infection ratio value. However, the number of InA is expected to be 
higher on the last infection days, as the parasites replicate continuously inside the host 
cell. The results did not confirm this hypothesis. This fact could be due to either non-
development of the intracellular amastigote parasite or to an artifact of the image analysis 
algorithm.  
To understand better this issue, some images were visually analyzed and the results 
were compared to the software analysis. It was observed that when the macrophage was 
infected with multiple parasites with short distance between them, the software was 
unable to detect all the parasites. In this sense, the data regarding the infection ratio 
could be still considered precise, as at least one parasite is always detected. Although, 
the ratio number of parasites per infected cells probably underestimated the number of 
intracellular parasites. To study the phenomenon of amastigote dynamics inside the 
macrophage, replication assays will be performed, so multiplication ratio of the 
intracellular parasites can be accurately observed. 
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Figure 40. Amastigotes’ growth dynamic. This graph shows parasite number per infected THP-1 cell over all 
post-infection days, with promastigotes from the 5th day of promastigotes’ culture. 
For Raw 264.7 cells, Figure 41, infection ratio should be read on the first days of 
infection, while there is still a reliable confluence of host cells in the well’s bottom. Also, 
number of parasites per infected cells should be quantified in 5th or 6th day post-infection, 
because, theoretically, it will have higher values. 
The optimal day for reading depends on the project’s purpose. For instance, if the aim 
is to evaluate a drug efficacy by measuring infection ratio, any post-infection day can be 
chosen. On the other hand, if the aim is to check if any given drug interferes with the 
amastigote’s replication ability inside the host cell, then, the final days of infection should 
be read from the 4th day on. 
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Figure 41. Amastigotes’ growth dynamic. This graph shows parasite number per infected Raw 264.7 cell over 
all post-infection days, with promastigotes from the 5th day of promastigotes’ culture. 
Figure 42 and Figure 43 show promastigote’s infection fitness on both cell lines. In 
these graphs, promastigote’s age is correlated simultaneously to parasite number per 
infected cell and infection ratio. The infection ratio marker represents a percentage of the 
total length of the bar itself, and the number of parasites is represented by the total bar 
length. The data indicates, once more, that the number of InA did not significantly 
increase along the infection course. 
 
Figure 42. Promastigote’s infection fitness in THP-1 cells. 
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Figure 43. Promastigote’s infection fitness in Raw 264.7 cells. 
Even though the results do not reflect entirely the amastigote’s replication dynamics, it 
can be seen some trend in the values obtained. Therefore, for THP-1 cells, the highest 
parasite number of parasites per infected cell in L. donovani, L. amazonensis, and L. 
braziliensis is the 6th day of promastigote’s in vitro culture, and in L. major is the 9th day. 
For Raw 264.7 cells, the highest parasite number of parasites per infected cell in L. 
donovani is the 4th day of promastigote’s in vitro culture, in L. major is the 7th day, in L. 
amazonensis is the 6th day, and L. braziliensis is the 5th day. 
The following graphs (Figure 44, Figure 45, Figure 46 and Figure 47) show infection 
differences between THP-1 and Raw 264.7 macrophage cell lines. They correlate 
parasite number per infected cell with promastigote culture day. There is one graph per 
species. Infection ratio is represented by a percentage of the total bar length, and the 
number of parasites by the total bar length. 
 
Figure 44. L. donovani infection. 
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Figure 45. L. major infection. 
 
Figure 46. L. amazonensis infection. 
 
Figure 47. L. braziliensis infection. 
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From these figures, we can conclude that Raw 264.7 cells tend to lead to higher 
number of parasites inside the host cell. Nevertheless, as it was mentioned before, these 
results are not as reliable or as consistent as THP-1 results. Raw 264.7 cells keep on 
multiplication, even after infection, and after reaching the maximum density cells start to 
die, leading to the appearance of cellular debris or nuclear artifacts that end up being 
wrongly identified as parasites. These results stress once more the need to estimate InA 
with some other technical means, in order to have more accurate and precise results.  
However, for all species, THP-1 and Raw 264.7 cells provide the same range of 
infection ratio and parasite number per infected cell, suggesting that the process is more 
parasite than host cell dependent. 
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4. Replication Assays 
On this subchapter, we show preliminary results obtained during replication assays. 
The aim was to establish amastigote doubling population time using this method. This 
way, it will be possible to overcome limitations imposed by software-automated analysis. 
These experiments lack automatization, but provide better resolution images and are 
consequently more accurate to measure amastigote’s replication dynamics during post-
infection period. The replication assay was based in immunofluorescence. After infection 
was stopped, BrdU was added to infection coverslips for 12 hours. Due to its similarity to 
thymidine, cells incorporate BrdU bases during replication and new DNA strands will bear 
them. Then, incubation with anti-Br antibodies primes these newly incorporated DNA 
bases. Alexa Fluor 488 antibody mark anti-Br sites and provide a green fluorescence 
signal. DAPI stains DNA strands both in host cell and parasites. 
In Figure 48, preliminary images from replication assay are shown. These images 
were taken 24 hour post-infection. In blue, host cell and parasite DNA is stained with 
DAPI, and in green replication sites are tagged. 24 hours post-infection, there is a clear 
overlap of parasite nuclei and replication sites. Therefore, we can state that all 
Leishmania species used in this project, started replicating inside host cells, THP-1, in a 
period inferior to 24 hours after infection. 
L. donovani L. major
L. amazonensis L. braziliensis  
Figure 48. Replication assay images for 24 hours post-infection in THP-1 cells. 
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 VII – Conclusion 
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This optimization carried in this project was never done before and it has a great 
scientifical value for many fields of research. Because our group is focused in drug 
discovery, obviously, these results will be very useful for this purpose. Now, we will be 
able to have optimized infection models, in order to get better results during HTS. As was 
mentioned before, HTS success relies deeply in a consistent, reproducible and robust 
biological model. 
On the other hand, these infection dynamics differences identified between species 
can point to very important biological behavior strategies. Leishmania parasites can in 
fact promote a wide range of disease clinical manifestations. Our results might correlate 
some tropism preferences with infection conditions. For instance, L. donovani parasites 
replicate and infect in higher rates at 37 °C, more than the other species. This is because 
L. donovani is viscerotropic and the other species studied have higher skin tropism. 
Therefore, these first results can be the basis and origin of many other studies, in HTS or 
in pure biology research fields. 
This project results provide better infection protocols for 4 Leishmania species in 2 
macrophage cell lines. The parameters optimized for each possible infection are 
represented on Table 7. 
Table 7. Optimal infection protocol for L. donovani, L. major, L. amazonensis, and L. braziliensis in THP-1 and 
8. Raw 264.7 cells. 
   Promastigote's Age 
Promastigote's 
Incubation 
Temperature 
Post-Infection 
Day 
THP-1 5 28 °C 4 to 6 
L. donovani 
Raw 264.7 5 28 °C 3 or 4 
THP-1 5 34 °C 4 to 6 
L. major 
Raw 264.7 5 34 °C 3 or 4 
THP-1 5 28 °C 4 to 6 
L. amazonensis 
Raw 264.7 5 28 °C 3 or 4 
THP-1 5 34 °C 4 to 6 
L. braziliensis 
Raw 264.7 5 34 °C 3 or 4 
Regarding the amastigote dynamics, it is not yet entirely possible to conclude some 
solid result, due to analysis limitations. However, further studies are already going on and 
will hopefully answer our questions. Other optimized parameters showed very consistent 
results and our further experiments will use them as starting point. 
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We shall also choose THP-1 over Raw 264.7 cells. In all results we obtained, THP-1 
cells always showed better phenotypic characteristics and, therefore, they always led to 
more precise and accurate results. Also, THP-1 cells are derived from human 
macrophages. So, infection obtained with this cell line will be closer to real human 
leishmanial infection. This way, HTS will be driven to get new drug scaffolds, targeting, 
more accurately, towards human infection and its specificities. 
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